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Abstract: 
Background: Asthma is a bronchial inflammatory disease. Asthmatic 
patients tend to have increased oxidative stress caused by imbalance 
between oxidants and antioxidants. Micronutrients are essential 
components of antioxidant enzymes that eliminate excess overproduced 
oxidants. 
 Objectives: To determine serum level of micronutrients Se, Zn, Cu, Mg, 
and antioxidant enzymes Gpx1 and Cu/Zn SOD in asthma patients and to 
compare them with the level in healthy controls. Further, to elucidate if the 
severity of asthma and the acute attack would change the level of these 
micronutrients and antioxidant enzymes. 
Methods: This is a case control hospital based study conducted during the 
period of 2006-2009 among 196 cases 97 females and 99 males, and 225 
controls, 90 females  and 135 males. The age range of the study subjects 
was between 18-70 years old with a mean of 37.5 ± 13.5 (mean ± SD). 
 Patients were selected from asthma clinics and emergency asthma rooms 
in AL Shaab and Omdurman Teaching hospitals. Information about 
demographic and clinical characteristics was collected from each patient 
using a questionnaire. The work was conducted in two stages. In stage 1, 
serum Mg, Se, Zn, and Cu were measured in asthmatic patients, most of 
them were selected from emergency rooms while introduced to asthma 
therapies, and from controls. In stage 2, serum micronutrients Se, Zn, Cu 
and their related antioxidant enzymes were evaluated in groups of patients 
who were clinically classified according to asthma severity to severe and 
mild cases, and according to the existence of steady state and acute 
exacerbation into patients during acute attack and patients in a stable 
period. 
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Serum micronutrients were measured using atomic absorption 
spectrophotometric methods. Serum antioxidant enzymes Gpx1 and Cu/Zn 
SOD were measured using ELIZA kits. 
Results: In stage 1, mean serum Zn was significantly higher in patients 
than in controls (1.2 mg/L and 0.94 mg/L) respectively. Mean serum Se 
was significantly lower in patients compared to controls (0.65 mg/L and 
0.78 mg/L) respectively. Mean serum Cu was significantly lower in 
patients than in controls(0.62 mg/L and 0.82 mg/L) respectively, while 
there was no significant difference in serum Mg compared to controls 
(1.644 mg/L and 1.634 mg/L) respectively. In stage 2, when clinically 
grouping the patients, serum Se, Zn, and Cu were found significantly low 
(p= 0.001) in severe asthmatic patients compared to controls. Serum Se and 
Zn were increased, but not statistically significant, during acute 
exacerbation and introduction of asthma therapies, while serum Cu did not 
change. Serum antioxidant enzyme Cu/Zn SOD was low in patients 
compared to controls, with a lower level during acute attack  , while 
increased levels in stable and severe cases were found but the differences 
were not statistically significant. Serum antioxidant enzyme Gpx1 was 
found significantly low in patients compared to controls, and significantly 
low of cases in acute attack compared to stable cases (p= 0.001), while it 
was low in severe cases but not statistically significant. 
Conclusion and recommendations: These results showed that, there was 
deficiency in the antioxidant enzymes Cu/ZnSOD and Gpx1 and their 
related micronutrients Zn and Se, in asthmatic patients compared to 
controls. The results also showed improvement in Cu/ZnSOD in the severe 
cases that were subjected to regular therapies. Zn increase in cases during 
the acute phase, while they were introduced to asthma drugs. This suggests 
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that proper supplementations of these micronutrients might increase the 
efficiency of the antioxidant defense system. 
Regular treatment with asthma drugs might decrease the oxidant stress in 
these patients by increasing the accumulations of the micronutrients and 
their related antioxidant enzymes.  
 
  
 XI
 
  ﻤﺴﺘﺨﻠﺺ اﻟ
ﺧﺎﺻﺔ اﺛﻨﺎء هﻨﺎﻟﻚ دور آﺎﻣﻦ ﻟﻠﻤﺆآﺴﺪات ﻓﻲ ﻧﺸﺎة او ﺗﻮﻟﺪ ﻣﺮض اﻟﺮﺑﻮ اﻟﺸﻌﺒﻲ  
وان اﻟﻤﻌﻠﻮﻣﺎت اﻟﺒﺤﺜﻴﺔ  اﻟﻤﻮﺟﻮدة ﻗﺪ اﺛﺒﺘﺖ ان اﻟﻌﻨﺎﺻﺮ اﻟﻀﻴﻠﺔ و .  اﺛﺎرﺗﺔ او ﺗﻔﺎﻗﻤﻪ
ﻣﻀﺎدات اﻻآﺴﺪة  اﻟﻤﺮﺗﺒﻄﻪ ﺑﻬﺎ  ﻗﺪ ﻳﻜﻮن  ﻟﻬﺎ دور ﻓﻲ  ﻋﻼج ﻣﺮض اﻟﺮﺑﻮ اﻟﺸﻌﺒﻲ  
  .وﺧﺼﻮﺻﺎ ﻋﻨﺪ ﺗﻔﺎﻗﻤﻪ
 اﻟﺰﻧﻚ,هﺬﻩ اﻟﺪراﺳﺔ ﺻﻤﻤﺖ ﻟﺘﺤﺪﻳﺪ ﻗﻴﻢ  ﻣﺴﺘﻮي اﻟﻌﻨﺎﺻﺮ اﻟﻀﺌﻴﻠﻪ  وهﻲ : اﻻهﺪاف
 nZ uC و  xpG اﻟﺴﻠﻴﻨﻮم و اﻟﻤﻐﻴﻨﺰﻳﻮم و اﻻﻧﺰﻳﻤﺎت ﻣﻀﺎدات اﻻآﺴﺪﻩ وهﻲ  ,اﻟﻨﺤﺎس,
. ﻓﻲ ﺳﻴﺮم  ﻣﺮض اﻟﺮﺑﻮ اﻟﺮﺋﻮي وﻣﻘﺎرﻧﺘﻪ ﺑﺴﻴﺮم ﻣﻦ اﺷﺨﺎص اﺻﺤﺎء DOS  
وﺗﻮﺿﻴﺢ اﻟﺘﻐﻴﺮ اﻟﺬي ﻳﻄﺮا ﻟﻤﺴﺘﻮئ هﺬﻩ اﻟﻤﻮاد ﻣﻦ اﻟﺴﻴﺮم ﻓﻰ ﻣﺨﺘﻠﻒ درﺟﺎت ﺗﻔﺎﻗﻢ 
  .اﻟﻤﺮض
 اﺟﺮﻳﺖ  ﻓﻲ ﻣﺴﺘﺸﻔﻲ اﻟﺸﻌﺐ و.اﻟﻤﺴﺘﺸﻔﺊ   هﺬة دراﺳﻪ ﺣﺎﻟﺔ ﺿﺎﺑﻂ اﺳﺎﺳﻬﺎ: اﻻﺳﺎﻟﻴﺐ
 522ﺣﺎﻟﺔ و  691وﻗﺪ ﺗﻀﻤﻨﺖ  .6002 -9002اﻣﺪرﻣﺎن اﻟﺘﻌﻠﻴﻤﻲ ﻣﻦ اﻟﻔﺘﺮﻩ ﺑﻴﻦ  
ﺛﻢ اﺧﺘﻴﺎر .  5.73+  50.31 ﺳﻨﺔ ﻣﺘﻮﺳﻂ  07‐81ﺿﺎﺑﻂ ﺗﺘﺮاوح اﻋﻤﺎرهﻢ ﺑﻴﻦ 
   .اﻟﻌﻴﺎدات اﻟﻤﺤﻮﻟﺔ ات اﻟﺨﺎﺻﻪ وﻏﺮف اﻟﻄﺆاري داﻟﺤﺎﻻت ﻣﻦ اﻟﻌﻴﺎ
واﻟﻄﺒﻴﺔ اﻟﺘﻲ ﺗﺘﻌﻠﻖ ﺑﺘﺎرﻳﺦ اﻟﻤﺮض واﻻدوﻳﻪ ﻗﺪ ﺗﻢ ﺟﻤﻌﻬﺎ اﻟﻤﻌﻠﻮﻣﺎت اﻻﺣﺼﺎﺋﻴﻪ 
اﻟﺤﺎﻻت . ﺮض ﺗﺼﻨﻴﻒ اﻟﻤﺮضﻐﺑﻮاﺳﻄﺔ اﺳﺘﺒﻴﺎن و ﺑﻤﺴﺎﻋﺪة  ﻣﻠﻔﺎت اﻟﻤﺮض  ﺑ
واﻳﻀﺎ  (ﺣﺎد وﺿﻌﻴﻒ ﻲﻣﺮﺿ )ﻣﺼﻨﻔﻴﻦ ﺣﺴﺐ  اﻟﺘﻘﺎرﻳﺮ ﺑﻤﻠﻔﺎﺗﻬﻢ  ﻰﺗﺘﻀﻤﻦ ﻣﺮﺿ
ﻏﻴﺮ ﻣﺼﻨﻴﻔﻴﻦ وﻟﻜﻦ ﻏﺎﻟﺒﻴﺘﻬﻢ آﺎﻧﻮا ﻣﺮض ﻣﻮﺟﻮدﻳﻦ ﺑﻐﺮف اﻟﻄﺆاري   ﺊهﻨﺎﻟﻚ ﻣﺮﺿ
  .ﻲ اﻟﻌﻼج وهﻢ ﻓﻲ ﺣﺎﻟﺔ ﺗﻔﺎﻗﻢ او اﺛﺎرﻩ ﻟﻠﻤﺮضﻟﺘﻠﻐ
اﺟﺮي ( ﻣﻐﻴﻨﺰﻳﻢ   –ﻧﺤﺎس   - ﺳﻠﻴﻨﻮم  ‐  زﻧﻚ  )ﻴﺎس ﻣﺴﺘﻮي  اﻟﻌﻨﺎﺻﺮ اﻟﻀﺌﻴﻠﻪ ﻣﻘ
ﺎدات ﻧﺰﻳﻤﺎت ﻣﻀﻴﺎﺳﺎت ﻣﺴﺘﻮي اﻻﻘﻣو .ﺑﻮاﺳﻄﺔ  اﺳﺘﺨﺪام ﺟﻬﺎز اﻻﻣﺘﺼﺎص اﻟﺬري
  .اﻻآﺴﺪﻩ  اﺟﺮﻳﺖ  ﺑﻮاﺳﻄﺔ اﺳﺘﺨﺪام   ﻣﺠﻤﻮﻋﺎت اﻻﻟﻴﺰا
 X
 
ﺖ ﻋﻦ  اﻧﺨﻔﺎض ﻣﻠﺤﻮظ ﻓﻲ ﻗﻴﻢ ت  ﻣﻘﺎرﻧﺔ  ﺑﺎﻟﻀﻮاﺑﻂ  آﺸﻔاﻟﺤﺎﻻ ﻣﺠﻤﻮﻋﻪ :ﺞ ﺋاﻟﻨﺘﺎ
واﻳﻀﺎ .اﻟﺴﻴﻠﻨﻮم واﻟﺰﻧﻚ  ﻣﻊ ﺗﺤﺴﻴﻦ اﻟﻤﺴﺘﻮي  اﺛﻨﺎء ﺗﻔﺎﻗﻢ اﻟﻤﺮض  وﺗﻌﺎﻃﻲ اﻟﻌﻼج 
اﻟﻨﺤﺎس ﻓﻬﻮ ﻣﻨﺤﻔﺾ اﻧﺨﻔﺎض  ﻣﻠﺤﻮظ ﻣﻦ آﻞ اﻟﺤﺎﻻت وﻟﻜﻦ  ﻟﻢ ﻳﺘﻐﻴﺮ اﺛﻨﺎء ﺗﻔﺎﻗﻢ 
 اﻧﺰﻳﻢ ال . اﺑﻂﺑﺎﻟﻨﺴﺒﻪ ﻟﻠﻤﻐﻴﻨﺰم ﻟﻴﺲ هﻨﺎﻟﻚ  اﺧﺘﻼف ﺑﻴﻦ اﻟﺤﺎﻻت واﻟﻀﻮ. اﻟﻤﺮض
 DOS nZ/UC
  آﺸﻒ ﻋﻨﺪ اﻧﺨﻔﺎض ﻓﻲ ﻣﺠﻤﻮﻋﺔ اﻟﺤﺎﻻت ﻣﻘﺎرﻧﺔ ﺑﺎﻟﻀﻮاﺑﻂ  ﻣﻊ اآﺜﺮ  اﻧﺨﻔﺎﺿﺎ   
اﻧﺨﻔﺎض  آﺸﻒ ﻋﻦ 1XPG اﻧﺰﻳﻢ ال. ت اﻟﺤﺎدﻩ واﻟﻤﺴﺘﻘﺮﻩوﻟﻜﻦ ﻳﺮﺗﻔﻊ ﻓﻲ اﻟﺤﺎﻻ
   .ﻣﻠﺤﻮظ ﻣﻦ ﺟﻤﻴﻊ  ﺣﺎﻻت اﻟﻤﺮض ﻣﻘﺎرﻧﺔ ﺑﺎﻟﻀﻮاﺑﻂ
ﻣﺮض اﻟﺮﺑﻮ  ﺗﺼﺎﺣﺐهﺬﻩ اﻟﻨﺘﺎﺋﺞ اوﺿﺤﺖ  وﺟﻮد وﻃﺎة اآﺴﺪﻩ  :اﻻﺳﺘﻨﺘﺎج واﻟﺘﻮﺿﻴﺢ
آﺴﺪات  ﻣﻨﺨﻔﻀﻪ  وهﺬا ﺑﻮازي ﺆوان ﺳﻌﺔ اﻟﺪﻓﺎع اﻟﻤﻀﺎدﻩ ﻟﻤﻔﻌﻮل اﻟﻤ.اﻟﺸﻌﺒﻲ 
اﻟﺒﺮاﻣﺞ اﻟﻐﺬاﺋﻴﺔ  ﻣﻮﺻﻲ ﺑﻬﺎ ﺑﺎﻻهﺘﻤﺎم  ‐ﻧﻚ ﺰﻴﻨﻮم واﻟﻠﻨﻣﺴﺘﻮي  اﻟﺴ ﻓﻰاﻻﻧﺨﻔﺎض 
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1. Introduction 
In the last few years nutrition has represented an important conditioning 
factor of many cardiovascular, gastrointestinal, and chronic pulmonary 
diseases particularly bronchial asthma.(1) 
Research has demonstrated that nutrition plays a crucial role in the 
prevention of chronic diseases, as most of them can be related to diet. Food 
is not only necessary for living but also as a source of mental and physical 
well-being, contributing to the prevention and reduction of risk factors for 
several diseases or enhancing certain physiological functions, this has 
initiated the concept of functional food .In reference to the immune system, 
many studies have pointed that micronutrients contribute to an enhancement 
of immuno- competence. It has been hypothesized that dietary constituents 
influence the immune system.(2) 
Many studies have suggested environmental factors, including diet are 
important in the development of asthma. The process of inflammation that 
takes place in the lungs of people with asthma, results in a situation called 
oxidative stress, which causes further injury to the tissues. Oxidative stress 
in the lungs is also increased by the pollutants present in the atmosphere, as 
well as by the normal functioning of mitochondria. Thus, it has been further 
suggested that the increase in asthma in recent times is due to our diet 
becoming less rich in antioxidants as processed foods increasing become 
consumed in preference to fresh foods.(3) 
1.1. Asthma 
1.1.1. Definition of asthma 
Bronchial asthma is an inflammatory disorder in which genetic and 
environmental factors play an important role. It is a chronic inflammatory 
airway disease characterized by an intense eosinophilic inflammatory 
infiltrate on bronchial mucus membrane. There is also infiltration of the 
airways with T-cells, mast cells, basophiles, and macrophages. Airway 
smooth muscle hyperatrophy and hyperplasia are characteristic of asthma 
that leads to thickening of the airway wall and obstruction of airflow.(4) It is 
characterized by increased mucus production and airway hyper 
responsiveness resulting in decreased air flow, and marked by recurrent 
episodes of wheezing, coughing, and shortness of breath. It is a multi-
factorial disease associated with genetic, allergic, environmental, infectious, 
emotional, and nutritional components. Because of their symptomatology 
the majority of individuals with asthma experience a significant number of 
missed work or school days. This can create disruption in quality of life, 
often leading to depressive episodes. It also disrupts the lives of care givers 
and family members of the affected individual. Asthma patients who have 
increased symptomatology at night also tend to have disturbed sleep patterns 
and impaired day attention, concentration and memory.(5) Although asthma 
is a chronic obstructive condition, unlike other COPD, the airway 
obstruction in asthma is usually reversible and affects the bronchi and not 
the alveoli.(6) 
1.1.2. History of asthma 
The word asthma gets its origin from Greek word (aazein) which means 
sharp breath. The first person to use it in the medical term was Hippocrats. 
Circa 450 BC, he was the first to call the disease asthma. During the 1930s-
50s, asthma was counted as one of the holey seven psychosomatic illnesses.(7)  
1.1.3. Epidemiology of asthma 
1.1.3.1. Prevalence of asthma 
Bronchial asthma is becoming a major health issue in many developing 
countries. There have not been reliable epidemiological studies to define the 
magnitude of the problem in many developing countries. Rates vary between 
3% and 30% depending on the location and methods of survey. Increases in 
the prevalence of symptoms of asthma in Africa, Latin America, and parts of 
Asia indicate that the global burden of asthma is continuing to rise, but the 
global differences in prevalence are decreasing.(8) 
Asthma is also an increasing global health burden, especially in the Western 
world.(9) According to survey data for which the diagnosis of asthma was 
based on a physician assessment, it is estimated that approximately 7% of 
Americans have current asthma. The disease affect people of all races and 
ethnic groups worldwide, from infancy to old age, with slightly more boys 
than girls affected and after puberty, more women than men.(10) 
Dramatic increases in the prevalence of atopy and asthma have occurred 
over the past few decades in Westernized countries and more recently in less 
developed nations. Estimates suggest that as many as 300 million persons 
are affected worldwide. (11) 
In 1998 it was estimated that asthma affected 17.3 million individuals in the 
United States and 150 million worldwide. From 1980-1995 the incidence of 
asthma in children under age of 18 years increased five percent per year, 
resulting in an increase of more than 100 percent in that time period, 
according to the National Health Interview Survey (NHIS). The current 
overall prevalence in children is estimated at 6.0-7.5 percent, with a total of 
over five million children affected. Asthma is the fourth leading cause of 
disability in children, and one of the most common reason for school 
absenteeism. The prevalence in adults is approximately five percent. Asthma 
prevalence among African-Americans is considerably higher than 
Caucasians or Hispanics, with black children having a 26% greater incidence 
than white children. Approximately 5,000 people die due to asthma.(12) 
Across racial and socioeconomic groups, the death rate for asthma mirrors 
the incidence, with African-Americans having the highest mortality from 
this disease .The death rates for asthma are higher in the inner city and in 
lower socioeconomic groups. The exact cause of these differences might be 
due to genetic, socioeconomic, and/or access to health care issues. Direct 
costs (doctors visits, hospitalization, drugs, etc.) of asthma vary, depending 
on the reference, but are estimated to be approximately $6 billion per 
year.(12) 
While asthma is more common in affluent countries, it is by no means a 
restricted problem; the WHO estimates that there are between 15 to 20 
million people with asthma in India. In the US urban residents, Hispanics, 
and African Americans are affected more than the population as a whole. 
Striking increases in asthma prevalence have been observed in population 
migrating from a rural environment to urban ones, or from a third world 
country to Westernized one.(13) 
1.1.3.2. Prevalence of asthma in Sudan 
According to the Annual Health Statistical Report of the Fedral Ministry of 
Health, asthma is one of the ten leading diseases of admission to the 
hospitals in Sudan(14) and the prevalence is 24%. The total numbers of 
patients being admitted for asthma were 34378 which is 4.7% of the whole 
admitted cases.(14) 
1.1.4. Classification of asthma: 
Asthma is clinically classified according to the frequency of symptoms, 
FEV1 and peak expiratory flow rate.(15) Asthma may also be classified as 
atopic (extrinsic) or non atopic (intrinsic), based on whether symptoms are 
precipitated by allergens (atopic) or not (non atopic) (16) (Appendix-I)  
Some people with asthma only rarely experience symptoms, usually in 
response to triggers, where other more severe cases  may have marked 
airflow obstruction all the time. Severity often correlates to an increase in 
symptoms.(11) 
1.1.4.1.  Classification of asthma severity  
Asthmatic patients usually present a history of intermittent wheezing, 
shortness of breath, and chest tightness. The severity of the disease is 
characterized in four groups of patients by a method proposed by the Global 
Initiative for Asthma.(11) 
This method was modified in order to include the characteristics of therapy 
in the classification of the severity of the disease. The four groups were as 
follows: 
I. Intermittent, comprises patients who are on ß² -adrenergic agents on 
demand. 
II. Mild persistent, comprises patients who regularly use ß²-adrenergic 
agents, with or without low dose of inhaled corticosteroids. 
III. Moderate persistent, comprises patients with a continuing history of 
episodic asthma, most of them are in regular inhaled corticosteroid 
therapy. 
IV. Severe, comprises patients with a current history of chronic 
unremitting asthma requiring high doses of inhaled corticosteroids 
and regular oral  corticosteroid therapy, or frequent short courses of 
oral corticosteroids.(17) 
1.1.4.2. Asthma Attack 
An acute exacerbation of asthma is commonly referred to an asthma attack. 
The cardinal symptoms of an attack are shortness of breath (dyspnea), 
wheezing, and chest tightness,(17) the former is often regarded as the primary 
symptom of asthma. Asthma exists in two states: The steady state of chronic 
asthma, and the acute state of an acute asthma exacerbation. The symptoms 
are different depending on what state the patient is? (17)  
 
1.1.5. Asthma patho physiology 
The lung is a major target organ for oxidant injury, because it is exposed to 
inhaled oxidant gasses and higher oxygen partial pressures than other 
tissues. (18, 19) Oxidative stress develops in the airways of asthmatics as 
inflammatory cells generate and release reactive oxygen species. Moreover, 
inflammatory cells from asthmatics generate more free radicals than those 
from non asthmatics.(20) 
The airway epithelium is a pseudo stratified columnar epithelium that lines 
our nasal passages and the conducting airways from the trachea to the large 
bronchioles. As well as being a protective barrier that separates the airways 
from the external environment, the epithelium produces many pro-and anti 
inflammatory substances.(21-23) Damage to the epithelium by oxidants 
released from inflammatory cells is a critical factor in the pathogenesis of 
airway inflammatory diseases such as bronchial asthma. In these diseases, 
excessive apoptosis may be a likely mechanism responsible for damage and 
sloughing of airway epithelial cells. Factors that increase the airway 
epithelium’s resilience to apoptosis are likely to lessen the severity of this 
disease.(24) 
The underlying patho-physiology of asthma, regardless of allergic 
components or triggering mechanisms, is airway inflammation. At the center 
of this improper inflammatory reaction is the T-cell. There is increasing 
evidence that the underlying process driving and maintaining the asthmatic 
inflammatory process is abnormal or inadequately regulated CD4+ T-cell 
immune response to otherwise harmless environmental antigens. The major 
CD4+ T-cell subset involved in this process is CD4+Th2 subset, which 
produces a series of cytokines (secondary mesenger molecules), including 
interlukin-4(IL-4), IL-5, IL-6, IL-9, IL-10, and IL-13. These cytokines 
stimulate the growth, differentiation, and recruitment of mast cells, 
basophiles, esinophils, and B-cells which are involved in humoral immunity 
and the allergic response. The other subset of CD4+ cells is the Th1 cell, 
which is responsible for production of interferon gamma (IFN-γ) and IL-2, 
which are involved in delayed hypersensitivity responses and cellular 
immune responses to intracellular parasites and viruses. It is not yet known 
precisely why individuals with asthma have this overriding Th2 activity. It 
may be that genetics, viruses, fungi, heavy metals, nutrition, and pollution 
all contribute to this debilitating and sometimes deadly disease process.(18, 19) 
The inflammatory process is also promoted when histamine and leukotrienes 
are released by mast cells. Histamine acts very quickly and stimulates 
bronco –constriction and excess mucus production. The end result of these 
complex interactions is a cascading immune and inflammatory response 
characterized by airway eosinophilia, mucus hypersecretion, and airway 
hyper-responsiveness-the hallmarks of asthma.(18, 19) 
Bronchial asthma is a major health problem it is characterized by chronic 
inflammation of the bronchi. Several factors have been implicated in the 
disease pathology and many studies have been carried out to elucidate the 
possible mechanisms leading to hypersensitivity, reversible obstruction of 
the airways, the activation of inflammatory cells, the synthesis of biological 
mediators and epithelial cell damage.(25) 
1.1.5.1. Reactive oxygen species (ROS) in asthma 
Inflammatory and immune cells in the airways, such as macrophages, 
neutrophils, and eosinophils, release increased amounts of ROS in asthmatic 
patients.(26-29) ROS can result in lung injury as a result of direct oxidative 
damage to epithelial cells and cell shedding.(19, 30) ROS have been shown to 
be associated with the pathogenesis of asthma by evoking bronchial 
hyperreactivity (31, 32) as well as directly stimulating histamine release from 
mast cells and mucus secretion from airway epithelial cells.(33) Furthermore, 
there is increased ROS during acute exacerbations of asthma.(34) Some of the 
potential triggers for asthma include viral infections, air pollutants such as 
ozone, and cigarette smoke .Other factors that can serve as promoters of 
ROS production in the airways of asthmatic patients include lipid mediators, 
chemokines, adhesion molecules, and eosinophil granule proteins. All of 
which, through ROS generation, trigger an increased inflammatory response 
producing asthmatic-like symptoms.(35, 36) Indeed, the actions of ROS can 
produce many of the pathophysiological features of asthma, including 
enhanced arachidonic acid release, airway smooth muscle contraction, 
increased airway reactivity and secretions, increased vascular permeability, 
and increased synthesis of chemoattractants.(31, 37) While much of the 
evidence for the involvement of ROS in the pathogenesis of asthma is 
indirect, numerous surrogate markers of oxidative stress have been 
measured. This includes markers such as exhaled H2O2 and NO products in 
breath condensate or in exhaled air (38, 39) which are elevated in asthmatics. 
Likewise, levels of 8-isoprostane or F2- isoponstanes are also increased in 
BAL fluid of patients with asthma.(40) However, while urinary excretion of 
15-F2-Isoprostane (8-iso Prostaglandin 2a, family of F2-isoprostanes) was 
increased in mild atopic asthmatics following inhaled allergen provocation, 
no increase was observed after inhalation of methacholine.(41) Neutrophils 
isolated from peripheral blood of asthmatic patients generate greater 
amounts of ROS than cells from normal subjects, and their ability to produce 
ROS correlates with the degree of airway hyperresponsiveness to inhaled 
methacholine (42, 43) Other inflammatory cells, particularly eosinophils 
derived from peripheral blood, also produce increased amounts of ROS and 
RNS after stimulation in asthma.(19, 26-29, 44) Moreover, in asthma, eosinophils 
are thought to play a critical role in the inflammatory response, as they are 
present in increased numbers in bronchoalveolar lavage (BAL) and blood 
that correlates with bronchial hyperresponsiveness (45, 46) Eosinophil 
activation in vivo results in eosinophil peroxidase (EPO) release and 
oxidative damage to proteins through bromination of tyrosine residues.(47) 
This is evident by the increased formation of 3-bromotyrosine on proteins, in 
response to the specific release of EPO from eosinophils reacting with 
oxidants in the BAL of patients with asthma. In contrast, neutrophil and 
monocyte-derived myeloperoxidase (MPO), which is increased in smokers 
and patients with COPD, produces 3-chlorotyrosine.(48) BAL fluid 
eosinophils, alveolar macrophages, and neutrophils from asthmatic patients 
produce more ROS (O2, H2O2, hypohalites), than do those from normal 
subjects.(49, 50) 
ROS can cause direct contraction of airway smooth muscle preparations and 
this effect is enhanced when the epithelium is injured or removed. Indeed, 
ROS mediated injury to the airway epithelium produces 
hyperresponsiveness of human peripheral airways, suggesting that ROS may 
play a role in the pathogenesis of asthma. This observation might provide a 
mechanistic link between epithelial injury arising from a variety of causes 
and airway hyperresponsiveness.(30) Moreover, these findings have been 
echoed in animal studies, which have shown that ROS may contribute to 
airway hyperresponsiveness by increasing vagal tone due to inhibition of 
adrenergic receptors and by decreasing mucociliary clearance,(37, 51) hence 
promoting airway inflammation and hyper reactivity. 
It has been postulated that increased levels of HOBr production as a result of 
EPO release from eosinophils results in increased peroxynitrite formation by 
interaction of HoBr2 NO. NO itself can be stored in cells as s-nitrosothiols 
(52) and this may regulate cellular apoptosis through inactivation of caspases 
by s-nitrosylation of critical cysteine residues (53) Consequently, increased 
peroxynitrite formation could deplete intracellular stores of NO, liberating 
active caspases that can then induce epithelial cell apoptosis and eventual 
hyperresponsiveness. This is supported by evidence showing that s-
nitrosothiol levels in asthmatics are significantly depressed (54, 55) However, 
another study showed that levels of NO in exhaled breath condensate were 
increased in asthmatics.(38, 56) This may simply reflect a 
compartmentalization effect, in that different mechanisms are operating in 
an intracellular versus extracellular environment. The precise mechanistic 
role that SOD inactivation by peroxynitrite plays in this is as yet unclear. 
However, it is postulated that SOD inactivation by peroxynitrite could 
increase the overall redox state by allowing higher levels of H2O2 to persist 
thereby depleting intracellular NO stores through increased peroxynitrite 
formation and lowering s-nitrosothiol levels.(57) Overall, this clearly shows 
that oxidant stress occurs in asthma, which can be reflected/detected both 
systemically and locally in the lungs. 
The balance between ROS production and antioxidant defense determines 
the intracellular environment which is responsible for the 
initiation/regulation of multiple physiological process within living systems , 
controlling functions such as signaling DNA and RNA synthesis, protein 
synthesis, enzyme activation and apoptosis.(57) 
In general, a low grade production of ROS (i.e., more reducing conditions),is 
associated with enhanced health, whereas, excessive ROS production and a 
chronic oxidative shift in the redox environment has been implicated in a 
wide variety of pathological conditions. This later scenario commonly 
referred to as oxidative stress, and occurs when ROS production is increased 
and or/antioxidant defenses are decreased. In fact oxidative stress is 
suggested to play a primary or secondary role in the pathophysiological 
mechanism of multiple acute and chronic human illness diseases.(57) 
 Fig. 1. Sources of oxidative stress. Oxidative stress derived from 
either environmental or cellular origins results in inflammation.(58) 
Cellular-derived oxidative stress can be produced through mitochondrial 
respiration, the NADPH oxidase system, or the xanthine oxidase system. 
Inflammation itself can have a feed-forward effect, triggering inflammatory 
cells to produce yet more oxidative stress, exacerbating and intensifying the 
inflammatory response. (57) 
1.1.5.1. Biochemistry of ROS 
ROS are oxygen-containing molecules that are capable of either accepting or 
donating a free electron, thus they are, to some extent, unstable and react 
with other molecules. This reaction may lead to the generation of other, 
sometimes even more reactive molecules. The first step in the complex chain 
of ROS is a one electron reduction of molecular oxygen. This leads to the 
production of superoxide, which is unstable and quickly undergoes another 
reduction to hydrogen peroxide H2O2, either spontaneously or in a much 
faster reaction catalysed by superoxide dismutase (SOD). H2O2 is relatively 
stable and can migrate from its site of origin; therefore it is capable of 
affecting a large scale of important cellular molecules. It can also turn into 
highly reactive hydroxyl radical (Fenton’s reaction, catalyzed by free 
iron).(59) 
Cellular injury caused by ROS is associated with their impact on cellular 
structure (membrane lipoperoxidation, DNA strand breaks) and function 
(changes in enzymatic activity, signalling). The effect of ROS depends on 
their concentration while structural changes need relatively high ROS 
concentrations (DNA strand breaks were seen with HO concentrations 
between 20–120 mol/L),(60) lower levels of ROS may modulate cellular 
processes involved in different types of injury such as proliferation, 
apoptosis and necrosis, that are controlled by so called redox regulation at 
the transcriptional level. The evidence that ROS regulate transcription 
factors NF-kB (61) and activation of protein 1 and p53 through the 
modulation of cellular redox state is already convincing.(62) 
An interesting example is the possible activation of lung mast cells by ROS 
at the onset of chronic hypoxia leading to increased production of 
metalloproteases and specific cleavage of collagen, which in turn triggers 
remodelling of pulmonary vessels.(63) 
1.1.5.2. Oxidant stress in asthma 
Oxidative stress is the hallmark of various chronic inflammatory lung 
diseases. Increased concentrations of ROS in the lungs of such patients are 
reflected by elevated concentrations of oxidative stress markers in the 
breath, airways, lung tissue and blood. Lung tissues are particularly 
susceptible to oxidative damage, because of direct contact with oxidants in 
ambient air. An individual´s ability to alleviate oxidative stress in tissues 
depends on endogenous enzymatic and non enzymatic pathways, as well as 
exogenous factors including the intake of antioxidant nutrients. Although 
there is abundant evidence that oxidative stress increases in a number of 
pulmonary diseases,(64, 65) there is limited population based evidence for the 
relation of oxidative stress biomarkers to pulmonary function. Lung 
represents a unique tissue for oxidant stress among most organs because it is 
directly exposed to higher oxygen tensions. Thus local oxygen partial 
pressure at the alveolar level is much higher than in other vital organs such 
as heart, liver, and brain. Oxygen pressure in the inhaled air is 20 kPa 
(150mm Hg) and is~ 13.3kPa (100mm Hg) at the alveolus, but it is ~6 
kPa(45mm Hg) in blood and may be as low as 1mm Hg in some sites within 
other organs. Another special feature of the lung is its large surface area 
(~70m² in the adult human lung).(66) 
Because of their direct exposure to ambient air, lung cell experience 
enhanced oxidant stress by environmental irritants and pollutants including 
oxidants such as cigarette smoke, ozone, and free radical generating 
carcinogens. In addition, a typical component in most lung disorders and 
lung infections is inflammation and activation of inflammatory cells with 
consequent free radical generation.(66) 
Many decades of research have produced a significant amount of data 
showing increased oxidative stress in asthma and indicating a potential role 
for oxidants in the pathogenesis of the disease, particularly during 
exacerbation. Putatively relevant pro-oxidative mechanisms have also been 
identified. Currently available asthma drugs are generally effective for the 
treatment of the disease, but their effects on oxidative stress have still not 
been elucidated. From the data available in the literature one can conclude 
that antioxidant compounds may have a potential role in the treatment of 
asthma, especially of asthma exacerbations. More convincing evidence from 
controlled clinical trials is required.(67) 
Oxidant generation is part of the normal metabolism of many types of cells 
and is critical for cell homeostasis. To protect itself against exposure to 
noxious oxidants, the lung has a well developed antioxidant system.(68, 69) 
When an imbalance occurs between oxidants and antioxidants in favour of 
oxidants, oxidative stress is said to occur. Many experimental and clinical 
data suggest that oxidants play a role in the pathogenesis of several 
respiratory disorders, including bronchial asthma. In particular, there is 
increasing evidence that the chronic airway inflammation typical of asthma 
results in an increased oxidative stress to the airways. Also many of the 
triggers for asthma exacerbations, including viral infections and air 
pollutants, may activate the production of oxidants, triggering increased 
inflammation which produces asthmatic symptoms.(67)  
The inflammatory cells recruited to the asthmatic airways have an 
exceptional capacity for producing oxidants. Once recruited in the airspaces, 
inflammatory cells may become activated and generate reactive oxidants in 
response to various stimuli. Activated eosinophils, neutrophils, monocytes, 
and macrophages, and also resident cells such as bronchial epithelial cells, 
can generate oxidants.(70-75) 
 The univalent reaction of oxygen to superoxide anion (O) is an important 
step in the formation of oxidants. As in many other inflammatory conditions, 
the oxidative burst in asthma is a non-specific process initiated by the 
concurrent action of numerous inflammatory pathways. Indeed, several 
asthma mediators including lipid mediators, chemokines, adhesion 
molecules, and eosinophil granule proteins are potential promoters of 
oxidant production.(71) 
In experimental models, oxidants can produce many of the features typical 
of asthma. They induce broncho-constriction and increase airway 
responsiveness to several agonists.(70, 75) The release into the airways of 
tachykinins and neorokinins and the decrease of β adrenergic receptor, 
cholinesterase, and neutral endopeptidase activities have been documented 
in these experimental conditions. Conversely reducing agents exert a 
relaxing effect on airway smooth muscle and can inhibit bronchial smooth 
muscle contraction and prevent airway hyperresponsiveness in several 
experimental models.(70) 
Mechanistically, the effect of oxidative stress on dendritic cells has been 
demonstrated to have a potent effect on Th1 /Th2 skewing of the immune 
response. Investigations of gene-environment interactions have identified 
genetic polymorphism associated with individual susceptibility to pollutant-
induced respiratory oxidative stress. The effects of current asthma therapy 
on oxidative stress are currently unclear, but previous trials using 
conventional antioxidant therapy in asthma have been largely ineffective. 
Preliminary data suggest that fullerene nanomaterials and dietary 
interventions may also have potential benefits in asthma.(76) 
Experimental exposure to oxidants induces many degrees of injury to 
bronchial epithelial cells until cell death. Eosinophil peroxidase can induce 
lysis of bronchial epithelial cells at concentrations that have been found in 
the asthmatic airways. Oxidants induce apoptosis of bronchial epithelial 
cells from asthmatic subjects.(70, 75) 
Many studies suggest that levels of oxidative stress are increased in children 
and in adults with asthma, not only in their lungs but also in their circulation. 
Many controlled studies suggest that there is a deficiency of antioxidants 
with few studies indicating an activation of the pathways protecting lung 
cells from oxidant mediated damage in the lung or circulation of asthmatic 
subjects.(77) For instance, a marked reduction in plasma antioxidant capacity 
occurs during exacerbations. In stable conditions, Cu/Zn-SOD is lower in 
steroid asthmatics than in normal subjects.(78) 
Most of the studies on oxidative stress in asthma have focused on the 
oxidant/antioxidant imbalance that occurs in stable asthma. The 
superimposed effects of exacerbations have received much less attention. 
Episodic worsening of asthma is associated with increased airway 
inflammation.(71) 
There is also evidence of enhanced oxidative stress during exacerbations, 
both systemically and locally. However, a direct correlation between 
increased oxidative burden and changes in pulmonary function and/or 
airway inflammation described during exacerbations remains speculative.(75) 
Numerous disturbances of antioxidant defense mechanisms have been 
described in asthma. For example, the expression of the asthma phenotype 
has been linked to reduced selenium status, an essential element for the 
normal activity of glutathione peroxidase, an insufficient dietary intake of 
vitamins with antioxidant properties, particularly in smokers.(79, 80)  
Decreased activity of copper and zinc containing superoxide dismutase( Cu-
Zn superoxide dismutase) in bronchial epithelial cells and BAL fluid cells 
has recently been found in asthmatic subjects not using inhaled 
corticosteroids compared with corticosteroid treated asthmatic patients and 
normal subjects. This was caused by altered expression of the enzyme.(78, 81) 
The recent literature in this field seems to indicate conflicting findings. 
Increased release of reactive oxygen species such as superoxide anion and 
hydrogen peroxide has been reported in exhaled breath condensates and 
from circulating granulocytes, and from the bronchoalveolar lavage cells of 
patients with asthma(82). In asthma, bronchial obstruction is associated with 
an increased spontaneous and stimulus-induced production of oxygen free 
radicals. The primary defense against reactive oxygen species is endogenous 
antioxidants, which are found to be altered in asthma. A marked decrease in 
plasma antioxidant capacity occurs. Superoxide dismutase activity is higher 
in erythrocytes and serum of asthmatic than in normal subjects and is 
diminished in cells from lavage and brushing samples of patients with 
asthma. Higher level of erythrocyte catalase activity has only been found in 
Nigerian asthmatic patients while decreased glutathione peroxidase activity 
has been well documented.(82) It was hypothesized that asthmatic individuals 
with higher levels of oxidative stress may have greater loss of SOD activity, 
which would be reflected systemically in loss of circulating SOD activity 
and clinically by development of severe asthma and/or worsening airflow 
limitation.(81) 
Understanding of the role of oxidative stress in asthma suggests that 
antioxidant therapy may be important in optimizing asthma treatment and 
prevention. The future success of antioxidant asthma therapy will require 
strategies with broad effects on airway redox equilibrium and the selection 
of appropriate target populations.(83) 
1.1.5.3. Antioxidant in asthma 
Antioxidants are compounds that hinder the oxidative processes and thereby 
delay or prevent oxidative stress.(84) They are effective because they are 
willing to give up their own electrons to free radicals. When a free radical 
gains the electron from an antioxidant it no longer needs to attack the cell 
and the chain reaction of oxidation is broken.(85) 
After donating an electron an anti oxidant become a free radical by 
definition. Antioxidants in this stage are not harmful because they have the 
ability to accommodate the change in electrons without becoming reactive.  
The human body has an elaborate antioxidant defense system. They are 
manufactured within the body and can also be extracted from the food 
humans eat such as fruits, vegetables, seeds, nuts, meats, and oil. 
There are two lines of antioxidant defense within the cell. The first line, 
found in the fat soluble cellular membrane consists of vitamin E, beta-
carotene, and coenzyme-Q.(86) Of these vitamin E is considered the most 
potent chain breaking antioxidant within the membrane of the cell. The 
second line, found inside the cell water soluble antioxidant scavengers. 
These include vitamin C, glutathione peroxidase, superoxide dismutase, 
(SOD) and catalase.(85) Practically every cell is endowed with mechanisms 
protecting it against the damaging effects of ROS. Antioxidants are 
recognized both intra- and extracellular and are divided into enzymatic and 
non-enzymatic categories as well.(85) 
Gutteridge and Halliwell classified antioxidants as primary (preventing 
oxidant formation), secondary (scavenging ROS) and tertiary (removing or 
repairing oxdatively modified molecules) which may be constitutive, 
inducible or dietary according to their origin.(87) 
The lung is directly exposed to the environment and to oxygen at higher 
partial pressure than other organs; its antioxidant defenses, therefore, is 
particularly important.(88) First in the line of enzymatic ROS degradation is 
superoxide dismutase (SOD). This enzyme exists in 3 forms – a) Cu/Zn 
SOD present mainly in cytosolic matrix, b) MnSOD localized preferentially 
in mitochondria and c) extracellular SOD. All SODs efficiently catalyze 
transformation of O– into HO yet its role in the antioxidant defense is not 
clear. Adding SOD was reported to enhance as well as to limit lipid 
peroxidation and membrane damage (89) which may result from different 
local concentrations of Fe+ and/or different concentration of enzymes 
protecting the cells against hydrogen peroxide. It is also clear that cells 
contain another enzyme protecting them against hydrogen peroxide. This 
function is fulfilled by the catalase and glutathione system. Catalase is 
localized intracellularly, especially in peroxisomes, and works efficiently 
under high concentrations of HO. In low concentrations it is mainly the 
reduced form of glutathione (GSH) that transforms hydrogen peroxide.(90) 
The ability of the glutathione system to reduce HO depends on the ratio 
between GSH and the oxidized form (GSSG), which in turn depends on two 
processes: transport of GSSG out of the cell and the capacity of GSH 
reductase – an enzyme which converts GSSG to GSH. The GSH 
concentration in the alveolar lavage fluid exceeds its plasmatic concentration 
by more than 100 fold (91) illustrating high capacity of this system in the 
lung. Regeneration of GSH requires reduced nicotinamid adenine 
dinucleotide phosphate (NADPH) that is supplied through endogenous 
antioxidant defenses within the lung. In order to combat the deleterious 
effects of ROS, various endogenous antioxidant strategies have evolved 
which employ both enzymatic and non-enzymatic mechanisms. The nature 
and composition of the antioxidant defenses will differ from tissue to tissue, 
as well as between environments, intracellular versus extracellular. Within 
the lung lining fluid several non enzymatic antioxidant species exist, which 
include glutathione, ascorbic acid (vitamin C), uric acid, α-tocophrol 
(vitamin E), and albumin. The relative abundance of these antioxidants can 
differ to that observed in blood plasma.(58) 
As the knowledge about ROS and their role in many pathologic processes 
grows, it is logical that many natural as well as synthetic substances are 
being tested in search of new therapeutic approaches utilizing their 
antioxidant properties. Among the most frequently investigated 
experimentally were glutathione.(92) A lot of researchers focused on 
enhancing enzymatic defense by administering SOD or catalase either 
intravenously or intratracheally.  Some of the agents were already used in 
small clinical trials on human patients with promising results like vitamin C, 
SOD and NAC.(93-97) Yet, so far none of them have become routinely used in 
clinical practice as there are still some confusing points to be resolved.(59) 
There is little doubt that ROS play an important role in pathogenesis of 
pulmonary diseases as well as many regulatory physiologic functions. Their 
importance depends on the subtle balance between ROS production and the 
defensive capacity of antioxidant systems. In addition, the location of their 
production also plays an important role. Many cells of the lung pulmonary 
tissue have the capacity to form ROS; however the real ROS sources in 
different pathological processes in the lung are far from being clear.(59) 
1.1.6. Role of micronutrients in asthma 
There is evidence that reactive oxygen species can be of particular 
importance in the pathophysiology of several lung diseases. Reactive oxygen 
species can even induce an autonomic imbalance between muscarinic 
receptor-mediated contraction and the beta-adrenergic-mediated relaxation 
of the bronchial smooth muscles.(98) Therefore, dietary, environmental, and 
genetic factors which diminish the cellular reducing capacity will increase 
tissue vulnerability to oxidant stress and are likely to increase the risk of 
asthma.(99) 
Since oxidative injury is a likely contributor to bronchial asthma, patients 
are best able to cope with oxidative stress through inactivation of free 
radicals.  Serum levels of Cu, Zn, Mg and Se might change in bronchial 
asthma, as these metals are important factors contributing in different ways 
to bronchial asthma.(99) 
1.1.6.1. Magnesium 
Magnesium is a metallic element of group 2 of the periodic table and has an 
atomic weight of 24.3. It is the eighth most abundant element in the earth’s 
crust. It is not found as a pure metal in nature, but it is found in large 
deposits as magnesite, dolomite, and other minerals. Magnesium is 
ubiquitous in foods, particularly those of plant origin, being an essential 
constituent of chlorophyll; however, the magnesium content vary 
substantially. Leafy vegetables as well as grains and nuts generally have 
higher magnesium content than meats and dairy products. A number of 
magnesium salts used as food additives. Water with increased hardness has a 
higher concentration of magnesium salts.(100) 
Tissue levels of magnesium are determined by atomic spectroscopy. The 
total body content of magnesium is 25 grams approximately 60% of that is 
present in bone, 20% is localized to the muscle and the remaining 20 % is 
present in soft tissue and liver. It has been estimated that 99%of total body 
magnesium is present intracellularly. Of the extracellular fluid magnesium, 
75% to 80% is filterable and 20% is protein bound. Normal plasma 
concentration of magnesium ranges between 1.7 -2.1 mg/L (0.7-
0.85mmol/l).(100) 
Magnesium and calcium play multiple dynamic roles in the pulmonary 
structure and function. When magnesium is deficient, the action of calcium 
is enhanced. In contrast, an excess of magnesium blocks calcium and vice 
versa.(23). Several mechanisms are implicated in the removal of cystosolic 
Ca. The uptake of Ca is dependent on ATP hydrolysis. Sarcoplasmic 
reticulum Ca Mg ATPase when phosphorylated binds 2Ca ions, which are 
then released. Mg is necessary for the activity of this enzyme as it binds to 
the catalytic site of it and mediate the reaction(23).  
  These interactions are important for patients with respiratory tract diseases 
because the intracellular influx of calcium causes bronchial smooth muscle 
contraction.(23) In this way, magnesium deficiency may be associated with 
increased contractility of smooth muscle cells. Since contractility of 
bronchial smooth muscle is important in patients with asthma, magnesium 
deficiency might negatively influence the clinical condition.(25) 
Magnesium is intimately involved with calcium metabolism. Calcium 
homeostasis is controlled in part by a magnesium-requiring mechanism 
which releases parathyroid hormone. Several magnesium activated enzymes 
are inhibited by calcium.  Magnesium transport into or out of cells appears 
to require the presence of carrier-mediated transport systems.(101) 
The efflux of magnesium from the cell is coupled to sodium transport and 
requires energy. Magnesium influx also appears to be linked to sodium and 
bicarbonate transport but by a different mechanism. Magnesium is absorbed 
along the entire intestinal tract, but the sites of maximal magnesium 
absorption appear to be the distal jejunum and ileum.(102) Both  an 
unsaturated passive and saturated active transport system for magnesium 
absorption may account for higher fractional absorption at low dietary 
intakes The kidney is the principal organ involved in magnesium 
homeostasis. Approximately 80% of plasma magnesium is unbound and 
available for glomerular filteration by the kidney.(103) 
Magnesium is a required cofactor for many enzyme systems. It is required 
for protein synthesis  and for both anaerobic and aerobic energy generation 
and for glycolysis, either indirectly as a part of magnesium ATP-complex or 
directly as an enzyme activator. Magnesium plays a multifunctional role in 
cell metabolism and cell division of various cell types which is highly 
dependant on the availability of extracellular magnesium It is important for 
maintaining an adequate supply of nucleotides for RNA and DNA synthesis. 
It is also necessary for sodium potassium-ATPase activity, and is also 
known to act as a calcium channel blocker Thus the magnesium depletion is 
linked to muscle cramps, hypertention and coronary and cerebral 
vasospasms.(104) 
Magnesium is the second most abundant intracellular cation, and it is a 
cofactor in >3000 enzymatic reactions involving energy metabolism and 
protein and nucleic acid synthesis. Serum magnesium contributes <1% to the 
total amount of the body, and its function as a marker for magnesium 
deficiency is doubtful. Therefore an increasing interest can be noted in the 
measurement of its intracellular concentration.(25) 
Magnesium has been shown to relax bronchial smooth muscle in vitro and to 
bronchodilate asthmatic airways in vivo On the basis of critical role of 
magnesium in the regulation of bronchial cell contractility via effect on 
calcium transport activation,(105) and phosphorylation/dephosphorylation 
intracellular reactions, it has been proposed that the intracellular magnesium 
content may determine the excitability of these cells. Magnesium deficiency 
may then lead to an increased excitability of bronchial smooth muscle with a 
consequent broncho-constriction.(106) 
Determination of serum magnesium concentration is the method that is 
generally used to detect altered magnesium homeostasis, despite the fact that 
only 1% of the total body content of this ion is found in the serum. 
Therefore, many studies have shown the superiority of measuring the 
intracellular content of magnesium over measuring serum concentrations in 
determining the magnesium status of patients. Intracellular content are 
measured in erythrocytes, as these cells represent the largest sub cellular 
compartment of blood cells, they contain magnesium in ionized-diffusible 
form, and they have been widely used in clinical studies.(107) 
1.1.6.2. Zinc 
Zinc is a metallic element with atomic number 30 and atomic weight of 
65.37 daltons. The adult body contains about 1.5 to 2.5 grams of zinc .It is 
present in all organs, tissues, fluids and secretion. Approximately 90% of 
total body zinc is found in skeletal muscle and bone and 6% in the skin. 
Over 95% of total body zinc is bound to proteins within cells and cell 
membranes. Plasma contains only 0.1% of total body. In plasma, 
approximately 18% of zinc is bound to alpha-2-macroglobulin, 80% to 
albumin and 2% to other proteins such as transferrin and ceruplasmin.(67) 
Zinc is an essential element in human and animal nutrition with a wide range 
of biological roles. Zinc plays catalytic structural or regulatory roles in more 
than 200 zinc metalloenzymes that have been identified in biological 
systems. These enzymes are involved in nucleic acid and protein metabolism 
and production of energy. Zinc plays a structural role in the formation of the 
so called zinc fingers. Zinc fingers are exploited by transcription factors for 
interacting with DNA and regulating the activity of genes. Another structural 
role of zinc is the maintenance of the integrity of biological membranes 
resulting in their protection against oxidative injury, among other things.(67) 
On average, absorption of zinc is around 20 to 40 percent of dietary intake, 
improving when zinc intake is low. Absorption also depends on the food 
source. More zinc is available from animal and zinc sources as these high 
protein foods contain amino acids which bind to zinc and make it more 
soluble. Zinc from vegetables, fruits and cereals is less well absorbed as 
these foods contain compounds such as phytates and oxalates which binds 
zinc and reduces the amount available for absorption. Zinc absorption 
decreases with age. People over 65 may absorb half as much zinc as those 
between 25 and 30 years old. Excretion of zinc is mainly via feces but some 
is lost in urine. Excessive sweating can causes losses up to 3mg per day.(68) 
The first consistent study investigating the zinc status of bronchial 
asthmatics was that of Goldey et al. in 1984 who reported a reduction in the 
zinc content of hair in asthmatics, but due to a limited sample size these 
results were not considered statistically significant.(74) 
However in 1987, a larger study by Di Toro and colleagues reported a 
significant decrease in zinc hair status in allergic and asthmatic children, 
suggesting that asthmatic children were at risk of zinc deficiency.(75)  
Further adding to these findings, el-Kholy et al. and Kadrabova et al. 
reported similar results, but extended the observations to show a significant 
drop in serum zinc levels .It was proposed that adequate dietary intake and 
zinc supplementation may decrease the severity of asthmatic attacks by 
correcting this underlying hypozincaemia.(73, 76) 
Several intrinsic factors may contribute to a low zinc status in asthmatics. 
First, like other inflammatory diseases, redistribution in plasma zinc to the 
liver can occur during excessive stress. This has been attributed to the 
release of leucocyte endogenous mediator from activated phagocytes, which 
then stimulates movement of zinc from plasma to hepatocytes in allergic 
reactions. Second, the immune system is extremely dependant on the 
availability of zinc for maintaining its homeostasis. Inflammatory diseases 
can cause an increase in the demand for zinc as: (i) Zinc is essential for 
producing the thymic hormone thymulin necessary for regulating T-cell 
development and activation; and (ii) zinc is crucial for the activation of 
natural killer cells, phagocytic cells, and for granulocytes, such as mast cells 
and eosinophils. As a result, greater demand for zinc by the immune system 
could be a contributing factor to the zinc deficiency noted in inflammatory 
diseases. Zinc deficiency itself is detrimental for inflammation as it results in 
dramatic increases in the number, size and activation state of mast cells.(75) 
This further exacerbates damage via chemotaxis of eosinophils and 
neutrophils, which creates a continuous cycle of oxidative damage. Zinc 
deficiency can also cause a premature switch from the Th1 dependant 
cellular immune response to a Th2 dependant pro-inflammatory humoral 
response. This shift in the Th1/Th2 balance promotes enhanced levels of IL-
4, IL-5, leukotriene B4 and prostaglandin E2 release, all of which have been 
implicated in promoting the pathogenesis of allergic diseases such as 
asthma.(75) 
Third, although reactive oxygen species are formed as a normal component 
of cellular respiration, in asthma there is a reported imbalance between the 
flux of oxidants generated and the presence and/or activation of cellular 
antioxidant defense mechanisms. This especially relates to Cu-Zn SOD, 
which is normally required to detoxify superoxide anions. There are studies 
which demonstrated a significant decrease in Cu-Zn SOD activity in 
erythrocytes and respiratory epithelial cells.(83, 108) One possible explanation 
for the decrease in activity of Cu-Zn SOD may be that in order for the body 
to compensate for increased oxidative stress, it must up regulate its 
antioxidant production, hence increasing its need for biochemically active 
zinc. Therefore if a hypozincaemia exists and tissue zinc becomes limiting 
during inflammation, the activity of Cu-Zn SOD may be compromised 
finally. The respiratory epithelial cells being rich in zinc, their loss, through 
shedding into the airways during asthmatic episodes, will further deplete 
zinc reserves. A special role for labile intracellular pools of zinc as anti-
apoptic agents in the regulation of the caspases, has emerged over the two 
past decades. Studies showed that zinc is strategically localized in the apical 
cytoplasm of airway epithelium to control caspase-3 activated apoptasis.(20) 
Possible mechanisms for zinc beneficial effects on asthma symptoms as it is 
a potent antioxidant and can act against conditions of oxidative stress and 
prevent the resulting injury and inflammation. Its antioxidant activity has 
four major effects: a) zinc stabilizes sulphadryl groups in proteins, which are 
the building blocks of cilia and tiny hairs lining the respiratory tract which 
help to shift mucus and pollutants out of the lugs, to prevent destruction. 
Accumulation of mucus is one of the factors causing asthma symptoms. b) 
Iron and copper within cell membranes can increase free radicals 
production; zinc neutralizes this activity and therefore makes the membranes 
more stable, which make the cells more resistant to injury. c) Zinc stimulates 
the body to produce metallothionein, which itself is an important 
antioxidant. (3) 
1.1.6.3. Copper 
Copper is a trace element essential for normal cell homeostasis. All living 
organisms require copper for growth and development. Copper being an 
integral cofactor for numerous enzymes that play key roles in various cell 
processes, including oxidative metabolism, neurotransmitter synthesis, free 
radical detoxification, and iron uptake. Either copper deficiency or copper 
accumulation is deleterious to the cells, and the intracellular concentration of 
copper is tightly controlled. (77) 
Copper is most concentrated in the liver, heart, kidneys, brain, bones, and 
muscles. It is also essential in the blood. Trace amounts are present in all 
body tissues. Copper increases iron assimilation. Iron and copper work 
together in the formation of hemoglobin and red blood cells. Some 
symptoms of copper deficiency may include; allergies and asthma. The 
decrease in serum copper level in asthmatics may be consequent upon the 
increased synthesis of caeruplasmin, a copper metalloprotein, which occurs 
in most inflammatory conditions involving free radicals.(78) 
Hence, serum copper is channeled into caeruplasmin synthesis to combat the 
oxidative stress in this pathological state. Moreover, copper is a component 
of the very important antioxidant enzyme superoxide dismutase (SOD) 
(Cu/Zn SOD) which ameliorates the deleterious effects of free radicals or 
reactive oxygen species.(78) 
It has been suggested that the dismutation of superoxide ions, as well as o f 
many metal compounds and non metal compounds, is catalyzed via a 
mechanism in which the metal or the non metal compound oscillates 
between two oxidation states. In this case, Cu² may oscillate between Cu² 
and Cu¹ or between Cu² and Cu³. In the current study however, it is clear 
that a decrease in this impairs the enzyme activity. Such a condition may 
cause oxidative stress or may further increase the existing stress.(73) 
1.1.6.4. Selenium 
Selenium is the essential trace element, which we largely obtain from bread 
and cereals, fish, poultry and meat, plays a vital part in many metabolic 
functions. While new research increasingly suggests its relevance to disease 
prevention, evidence that dietary intake is falling in some parts of the world 
is giving cause for concern.(109) 
Selenium is a key component of a number of functional selenoproteins 
required for normal health. It is of fundamental importance to human health. 
It is an essential component of several major metabolic pathways, including 
thyroid hormone metabolism, antioxidant defense systems, and immune 
function. The decline in blood selenium concentration in the UK and other 
European Union countries has therefore several potential public health 
implications, particularly in relation to the chronic disease prevalence 0f the 
Western world such as cancer and cardiovascular disease. Ten years have 
elapsed since recommended dietary intakes of selenium were introduced on 
the bases of blood glutathione peroxidase activity. Since then 30 new 
selenoproteins have been identified, of which 15 have been purified to allow 
characterization of their biological function.(110) 
The long term health implications in relation to declining selenium intakes 
have not yet been thoroughly examined, yet the implicit importance of 
selenium to human health is recognized universally. Selenium is 
incorporated as selenocysteine at the active site of a wide range of 
selenoproteins Se supplementation may influence immune responses to 
allergins by skewing the balance between Th1/Th2 differentiations, the 
balance between T effector/ T regulatory cell populations or a combination 
of these effects.(111) 
GSH anti-inflammatory activity is based on the elimination of 
hydroperoxides produced in the side of inflammation (scavenger of free 
oxygen radicals). (110) Selenium functions as a cofactor for the antioxidant 
enzyme glutathione peroxidase, which is proposed to counter oxidation and 
to reduce the synthesis and release of leokotriene B4, an inflammatory 
mediator.(112) Selenium may also along with vitamin C attenuate the 
activation of nuclear factor kappa-ß a transcription factor that regulates 
inflammatory cytokines associated with the asthmatic immune response.(113, 
114) 
Hasselmark et al performed a double blind, placebo-controlled study in 
which asthma patients were given 100 mcg sodium selenite (containing 46 
mcg elemental selenium) for 14 weeks. Significant increases were seen in 
serum and platelet selenium and GSH-Px activity, and improvements were 
seen in subjective symptomatology. However, objective measurements of 
lung function were not changed. It may be that the supplemental dosage 
given was too low and that a supplemental dose of 200-250 mcg might be 
more beneficial.(115) 
There is evidence that the activity of glutathione peroxidase is sub maximum 
at selenium concentration of less than 100ng/ml.(116) A selenium level of 80 
ng/ml is considered the minimum level necessary in the blood stream for 
maximum production of selenoproteins including Gpx.(117)  
1.1.7. Role of antioxidant enzymes in asthma 
Virtually every organism has defense systems to counterbalance oxidative 
stress. These involve numerous antioxidants endogenous enzymes. Among 
these enzymes are SODs and Gpxs. The activity of those enzymes can be 
regulated through several mechanisms e.g. through increasing transcription 
of the enzyme and/or through increasing its activity. Enzyme activity may 
increase in response to elevated usage under condition of acute oxidative 
stress or in response to trace elements re-supplementation following their 
deprivation.(118) 
The influence of glucocorticosteroids on antioxidant enzymes activity also 
been described. SOD and Gpx are reported to be regulated on a 
transcriptional level and this fact would correspond to the effects exerted by 
glucocortico steroids with pleiotropic influence on transcriptional and 
signaling pathways. Again due to the fact that the aforementioned enzymes 
are trace element dependant, glucocortico steroids might affect them through 
their influence on trace element accumulation.(119) 
1.1.7.1. Glutathione peroxidase:  
Glutathione peroxidase (Gpxs) ubiquitously expressed proteins which 
catalyze the reduction of hydrogen peroxides and organic hydroperoxides by 
glutathione.There are several iso forms which differ in their primary 
structure and localization: 
I. The classical mitochondrial Gpx1 (cGpx) is a selenium dependant 
enzyme, the first of the Gpx family to be dicovered. 
II. Gpx2 also known as gastrointestinal Gpx (GI-Gpx) is an intacellular 
expressed only in the epithelium of gastrointestinal tract. 
III. Extracellular plasma Gpx (pGpx or Gpx3) is mainly expressed in the 
kidney from where it is released into the blood circulation. 
IV. Phospholipid hydroperoxides Gpx4 (PH-Gpx) is expressed in most 
tissues and it can reduce many hydroperoxides.(120) 
Glutathione (GSH) is a vital antioxidant of the lung. The epithelial cells that 
line the lower respiratory tract have a protective screen of glutathine to 
protect against oxidant damage by free radicals. In fact early research 
showed that total glutathione (both GSH and oxidized GSSG) of normal 
epithelial lining fluid was 140 times higher than the glutathione found in the 
blood of the same person.(91) 
GSH a sulfhydryl-containing tripeptide produced by most mammalian cells, 
is an effective scavanger of ROS. Under appropriate conditions, an increase 
in one or more antioxidants might offset increases in oxidant production. 
Decreased peripheral blood GSH activity has been documented in patients 
with asthma.(91) 
Smith and his Co-workers(121) found increased amount of GSH in BAL fluid 
in patients with stable asthma amounts that were inversely correlated with 
bronchial hyperresponsiveness. Levels of antioxidants enzymes Gpx1, but 
not Gpx4, were more clearly influenced by the level of allergic airway 
inflammation. Gpx1 functions to detoxify peroxides in the cells, and its 
increased expression in asthma emphasizes the important role it plays in 
balancing the oxidative stress that occurs during allergic airway 
inflammation.(43) 
1.1.7.2. Cu/Zn SOD 
Superoxide dismutases (SODs) are a unique family of metalloproteins that 
catalyze the dismutation of superoxide anion radicals (O-) to O2 and 
hydrogen peroxide H2O2. 
O-2 +O-2 2H+=>H2O2+O2 
SOD is ubiquitous in oxygen metabolizing cells protecting these cells 
against direct and indirect oxygen mediated free radical damage. Four types 
of SOD have been defined on the basis of distinctions in their metal 
cofactors and distribution: MnSOD, Cu/Zn SOD, FeSOD, and ECSOD.(122) 
The properties of Cu/ZnSOD are quite different of those of the manganese 
or iron enzymes. The human Cu/Zn SOD is a dimeric protein composed of 
two subunits of 153 amino acid residues. Dissociation of the two subunits is 
facilitated by alkylation of the two sulfhydryl groups in the protein or by 
removal of the Cu and Zn ions. Cu/Zn SOD gene expression is induced by 
mediators of oxidative stress like sulfhydry-l antioxidants, interlukin-1, and 
tumor necrosis factor. Induction of Cu/Zn SOD expression resulting in 
elevated levels in human body fluids is of diagnostic value for measuring the 
activities of different diseases.(123) 
SODs play an important role in offering protection to the airways against 
oxidative stress. SODs get inactivated by reactive oxygen and nitrogen 
species. Thus antioxidant defense is impaired in hyperactive airways. The 
situation gets further aggravated during acute exacerbation of asthma. The 
inflammatory cells increase the production of ROS. There is localized 
decrease in SOD activity within inflamed asthmatic airways.(124) 
Recently, 2 studies by Comhair et al. have identified that impaired SOD 
activity has been found to be associated with airflow obstruction along with 
airway hyperresponsiveness and remodeling.(125, 126) 
Super oxide dismutases (SODs) are metalloenzymes that efficiently catalyse 
the dismutation of superoxide ions (o⎯) into oxygen and hydrogen peroxide. 
It is widely recognized that these enzymes, which ever present in all living 
organisms, provide a defence system that is essential for their survival under 
aerobic conditions.(127) SOD exists in several different compartments of the 
cell. The cytosolic enzyme is composed of two similar subunits, both of 
which composed of two similar subunits, both of which contain one 
equivalent of Cu² and Zn², where as the mitochondrial enzyme contains Mn², 
similar to the enzyme found in bacteria.(128) 
The essential first line antioxidant enzyme SOD is reduced in asthma as 
compared to healthy individuals, with lowest levels in those patients with the 
most severe asthma. Loss of SOD and catalase activity is related to oxidative 
modifications of the enzymes, while other antioxidant gene polymorphisms 
are linked to susceptibility to develop asthma.(129) 
When compared to healthy subjects it is apparent that superoxide dismutase 
(SOD) activity is significantly lower in the epithelial lining fluid and airway 
epithelial cells of asthmatic subjects. Indeed, when segmental antigen was 
instilled in the lung of an asthmatic suffering from atopic asthma, it was 
clear within a few minutes that loss of SOD activity had occurred.(130) This 
loss was due to the twofold increase in O2•– generation after antigen 
instillation into the airways of these atopic individuals. A link between the 
SOD activity levels and the level of airway reactivity has also been 
described. Earlier studies carried out in larger populations reported that 
airway reactivity is inversely related to SOD activity.(131) These findings 
support the notion that there is a link between SOD activity and physiologic 
parameters of asthma severity. Other studies have also indicated that the 
lower SOD activity in asthma occurred as a result of the increased oxidative 
and nitrosative stress in the asthmatic airways, which therefore can be used 
as a sensitive marker indicating the airway redox activity and asthma 
severity. When acute asthma attacks are taking place, there is an increase in 
the reactive oxygen and nitrogen species. It can therefore be inferred that the 
loss of SOD also contributes to oxidative stress during acute asthma 
exacerbations.(130) 
1.2. Rationale 
Bronchial asthma is becoming a major health issue in many developing 
countries, and increasing global health burden over the past few decades. 
Dramatic increases in the prevalence of asthma occurred in Westernized 
countries, and more  recently in  less developed nations.(11) 
Dietary factors have been proposed to play a role in the origin, progression 
and severity of established asthma. It is strongly suggested that serum 
antioxidant imbalance plays an important role in the etiology and prognosis 
of asthma and that antioxidants are increasingly consumed in bronchial 
asthma. It has also been hypothesized that a deficient antioxidant capacity 
may also play a role in the pathogenesis of asthma.(4) 
In this regard, there were many researches done in asthma in Sudan however 
oxidative stress in asthma and the effect of antioxidant trace elements and 
enzymes on asthma patients whether classified or not is not covered.  
  
1.3. Objectives: 
1.3.1. General objectives: 
This study was designed to explore the role of micronutrients and their 
related antioxidant enzymes in asthma disease and in relation to the clinical 
classification of asthma. 
1.3.2. Specific objectives: 
• to measure serum micronutrients Se, Zn, Cu, and Mg in asthmatic 
patients and compare it with controls. 
• to measure serum antioxidant enzymes Cu/Zn SOD and Gpx1 in 
asthmatic patients and compare it with controls.  
• to compare serum levels of micronutrients  Se ,Zn ,Cu, and 
antioxidant  enzymes between asthmatic groups to elucidate their role 
in asthma severity 
• to measure the levels of serum micronutrients Se, Zn, Cu, and 
antioxidant enzymes during acute symptomatic period of asthma and 
during asymptomatic stable period, to determine the change in their 
levels due to asthma attacks. 
2. Subjects and methods 
2.1. Study design 
This is a case control hospital based study, conducted in two stages: 
1- Stage 1 between June 2006 and April 2007. 
2- Stage 2 between April 2009 and Oct. 2009. 
2.2. Study area and population 
This study was conducted in asthma emergency rooms, referred clinics and 
ICU of chest departments of Alshaab and Omdurman Teaching Hospitals, 
between June 2006 and April 2011. These hospitals were selected, because 
asthma emergency rooms and clinics were well established and well 
equipped and large numbers of patients were attending it. All patients 
attending asthma rooms and clinics were approached. 
The control subjects were mainly co-patients, or workers in the hospitals 
matched for sex and age to cases. Inclusion and exclusion criteria were used 
to select the test and control groups. 
2.3. Sample size 
The sample size of study cases was 196 (97 females and 99 male), this 
include 100 cases for the first part of the study and 96 for the second part of 
the study. 
The sample size of the study controls was 225(135 males and 90 females). 
As there were no studies done in Sudan in this area, and the prevalence was 
not known, the sample size was based on the literature of studies found 
outside   of the Sudan. 
2.4. Inclusion and exclusion 
Inclusion criteria of the test groups: previously diagnosed adult asthmatic 
patients, age between 18-75, has no history of diabetes mellitus, or kidney 
disease, or thyroid disease or other chronic disease, not active smokers and 
no pregnancy for females 
Inclusion criteria of control groups: healthy and physically fit with no 
history of asthma, age between 18-70 and not active smokers and no 
pregnancy for females. 
Exclusion criteria of test groups:  diabetic, thyroid disease, kidney problems 
and pregnancy and active smoking. 
Both groups are matched for sex, age and area of residence. 
2.5. Methods  
2.5.1. Questionnaires 
Two questionnaires “Interviewer administered questionnaire paper” were 
prepared (Appendix-II & III). Data required by questionnaire were collected 
from each patient as follows: 
a-Demographic characteristic information about his age, his residential area, 
his occupation, and his address. 
b-Clinical information about, frequency of episodes, frequency of attendance 
to asthma clinics, drugs taken for control and the date of onset of asthma. 
Patients were classified according to asthma severity, existence of steady 
state and acute exacerbation, as follows: 
Mild, severe, symptomatic and asymptomatic. (11) 
2.5.2. Collection of blood samples 
Chemically clean and sterile disposable needles, syringes and swabs were 
used for all blood samples. Ten ml of blood was withdrawn from each 
selected study subject from the antecubital vein. The syringes were covered 
and labeled with the subject number. The blood was left at upright position 
in racks for the serum to separate for at least one hour in a cold place. 
The samples were sent immediately to the laboratory for centrifugation and 
storage prior to analysis. 
2.5.3. Serum separation and storage 
The separated serum was collected in labeled centrifuge tubes, and 
centrifuged using the simple bench macro-centrifuge within 2-3 hours of 
venipuncture. Serum samples were collected in labeled epindorff tubes and 
stored at -20 C for biochemical analysis. 
2.5.4. Technique of biochemical analysis 
Serum trace elements zinc, copper, selenium and magnesium were measured 
using atomic absorption spectrophotometer (AA 6800 Shimatzu company). 
The atomizer for selenium was furnace of palladium nitrate. The atomizer 
for Zn, Cu and Mg was flame of air acetylene fuel with gas flow rate of 
1.8L/min. (Appendix-IV). 
Serum antioxidant enzymes Gpx1 and Zn/Cu SOD were measured using 
commercially available quantitative sandwich enzyme- linked 
immunosorbent assay (ELIZA) kits according to instructions of 
manufacturers. The analysis’s were performed with 96-well micro titer plate 
ELIZA kits from Biovender Research and Diagnostic Products/CZECH 
REPUBLIC. 
2.5.4.1. Principles of method of assay of Gpx1 
The design of this assay is based on a sandwich Enzyme–Linked 
Immunosorbent Assay (ELIZA). The microtiter plate provided in this kit has 
been pre-coated with a monoclonal antibody specific to human Gpx1. 
Samples are pipette into these wells. Nonbound Gpx1 and other components 
of the sample should be removed by washing, then biotin conjugated 
monoclonal antibody specific to Gpx1 added. In order to quantitatively 
determine the amount of Gpx1 present in the sample, Avidin conjugated to 
horseradish peroxides (HRP) was then added to each microplate well. Next, 
tetramethylbenzidine (TMB) substrate solution was added to each well. 
Finally a sulfuric acid solution was added and the resulting yellow colored 
product was measured at 450 nm. The absorbance is directly proportional to 
the amount of captured Gpx1.(120, 132) (Appendix-V) 
2.5.4.2. Principles of method of assay of Cu/Zn SOD 
This is also based on ELIZA. An antihuman Cu/Zn SOD coating antibody is 
adsorbed onto micro wells. Human Cu/Zn SOD present in the sample or 
standard binds to antibodies adsorbed to micro wells. A HRP conjugated 
antihuman Cu/Zn SOD antibody is added and binds to human Cu/Zn SOD 
captured by the first antibody. Following incubation unbound HRP-
conjugated anti-human Cu/Zn SOD is removed during a wash step, and 
substrate solution reactive with HRP is added to the wells. A colored product 
is formed in proportional to the human Cu/Zn SOD present in the sample or 
standard. The reaction is terminated by addition of acid and absorbance is 
measured at 450nm. A standard curve is prepared from 7 human Cu/Zn SOD 
standard dilutions and human Cu/Zn SOD concentration determined.(123) 
(Appendix-VI) 
2.5.4.3. Principles of atomic absorption method 
The technique makes use of absorption spectrometry to assess the 
concentration of an analyte in a sample. It requires standards with known 
analyte content to establish the relation between the measured absorbance 
and the analyte concentration and relies therefore on Beer-Lambert Law. In 
short, the electrons of the atoms in the atomizer can be promoted to higher 
orbitals (excited state) for a short period of time (nanoseconds) by absorbing 
a defined quantity of energy (radiation of a given wavelength). This amount 
of energy, i.e., wavelength, is specific to a particular electron transition in a 
particular element. In general, each wavelength corresponds to only one 
element, and the width of an absorption line is only of the order of a few 
picometers (pm), which gives the technique its elemental selectivity. The 
radiation flux without a sample and with a sample in the atomizer is 
measured using a detector, and the ratio between the two values (the 
absorbance) is converted to analytic concentration or mass using Beer-
Lambert Law.(133, 134)  
2.6. Ethical consideration 
Ethical approval was given by the research committee (Faculty of Medicine, 
University of Khartoum). Permission letters were submitted to the chest 
departments of the selected hospitals. Written consents were obtained from 
study subjects before entry into the study. 
2.7. Statistical analysis 
All data obtained with questionnaire,   and biochemical analysis was 
analyzed using the statistical package for the social sciences (SPSS) Version 
14. The chi square test was used to test distribution of categorical variables 
and student’s t test was used to continuous variables. The differences 
between the test and control groups were assessed with the student’s t test. 
Statistical significance was accepted when P value is less or equal to 0.05. 
2.8. Data presentation 
Final results were presented in tables and figures. 
2.9. Declaration 
All questionnaires for data collection of this research and most technical 
methods were done by the researchers. These include obtaining permission 
from the selected hospitals to conduct the study, random selection of study 
groups, questionnaire application and collection of information from patient 
files, serum separation and storage, however, the technical parts that need 
special experience were done by well trained relevant personnel. Blood 
collection and advanced laboratory biochemical analysis were done by nurse 
and laboratory technicians. 
Most of the expenses were covered by funds donated from Research 
Departments in the Ministry of Education and University of Khartoum. 
3. Results 
3.1. Demographic characteristics of the study group 
3.1.1. Age distribution 
The ages of the study group ranged between 18-70 years old with a mean of 
37.1 ± 13.5 year (mean ±SD). The mean age for cases of stage 1 was 39.9 ± 
15.7 years, and for stage 2 classified cases was 40.2 ± 12.9 years. The mean 
age for stage 1 controls was 30.8± 10.2, and for controls of stage 2 was 
35.7± 13.2. 
3.1.2. Sex distribution  
The frequency of males in stage 1 cases was 53 and of females was 47, and 
the percentage was 53 % and47 % respectively. The frequency of males in 
stage 2 classified cases was 47.9 and of females was 52.1, and the 
percentage was 47.9 % and 52.1% respectively. 
The frequency of males in stage 1 controls was 107 and of females was 63, 
and the percentage was 62.2% and 36.8% respectively. The frequency of 
males of stage 2 controls was 28 and of females was 27, and the percentage 
was 49 % and 51 % respectively  
3.2. Clinical characteristics 
3.2.1. The distribution of Asthma duration in the study cases 
The frequency and percentage in cases of whom the duration of asthma was 
>20 years was 22 and 22% in stage 1 cases. It was 41 and 42% in stage 2 
classified cases respectively.  
The second part cases in whom the duration of asthma was 10-19 years the 
frequency and percentage was 45 and 46.9% respectively  
The frequency and percentage in cases of whom the duration of asthma was 
<10 years cases, 10 and 10.4% for the stage 2 classified cases respectively  
 
3.2.2. Asthma severity distribution 
The frequency and percentage of the mild persistent cases were 60 and 
63.2% respectively. The frequency and percentage of the severe persistent 
cases were 35 and 36.8% respectively (Fig.2). 
3.2.3. Presence of symptoms distribution 
The frequency and percentage of symptomatic cases were 57 and 63.4% 
respectively (Table 3). The frequency and percentage of asymptomatic cases 
33 and 36.6% respectively (Fig.3). 
3.2.4. Distribution of usage of asthma therapies in stage 1cases 
3.2.4.1. Bronchodilators 
The frequency and percentage of cases using bronchodilators were 52 and 
52% respectively. The frequency and percentage of cases not using 
bronchodilators were 48 and 48 %.(Fig.5). 
3.2.4. 2. Steroid inhaler 
The frequency and percentage of cases using steroid inhaler were 73 and 
73% respectively. The frequency and percentage of cases not using steroid 
inhaler were 27 and 27% respectively (Fig.6). 
3.2.5. Distribution of attendance of cases to asthma clinics 
The frequency and percentage of cases who attend asthma clinics were 51 
and 68.9% respectively (Table 4). The frequency and percentage of cases 
who do not attend asthma clinics were 23 and 31.1% respectively (Fig.4). 
3.3. Mean Serum level of trace elements of stage 1 study subjects 
3.3.1. Zinc 
Mean serum zinc of first cases and controls were 1.2 mg/l and 0.94 mg/L 
respectively. The mean was higher in the group of cases than in the group of 
controls, the difference was statistically significant and P value was 0.001 
(Fig.7). 
3.3.2. Copper 
Mean serum copper of cases and controls were 0.62 mg/l and 0.82mg/l 
respectively. The mean was lower in the group of cases than in the group of 
control, the difference was statistically significant and P value was 0.001 
(Fig.7). 
3.3.3. Magnesium 
Mean serum magnesium of cases and controls were 1.644 mg/l and 1.634 
mg/l respectively. There was no statistical significant difference between the 
mean of the group of cases and the group of controls and P value was 0.825 
(Fig.7). 
3.3.4. Selenium 
Mean serum selenium of cases and controls were 0.65 mg/l and 0.78 mg/l 
respectively. The mean was lower in the group of cases than in the group of 
controls, the difference was statistically significant and P value was 0.001 
(Fig.7). 
3.4. Mean serum SOD, Gpx1, Se, Zn and Cu of stage 2 study subjects 
3.4.1. Selenium 
Mean serum selenium of cases and controls was 0.51 mg/L and 1.03 mg/L 
respectively. The mean was lower in the group of cases than in the group of 
controls, the difference was statistically significant and P value was 0.001 
(Fig.9). 
3.4.2. Zinc 
Mean serum zinc of cases and controls was 0.62 mg/l and 0.82 mg/l 
respectively. The mean was lower in the group of cases than in the group of 
controls, the difference was statistically significant and P value was 0.001 
(Fig.9) 
3.4.3. Copper 
Mean serum copper of cases and controls was 1.01 mg/L and 1.5 mg/L 
respectively. The mean was lower in the group of cases than in the group of 
controls, the difference was statistically significant and P value was 0.001 
(Fig.9). 
3.4.4. Cu/Zn SOD 
Mean serum Cu/Zn SOD of cases and controls was 86.5µg/l and 87.6µg/l 
respectively. The mean was lower in the group of cases than in the group of 
controls, the difference was not statistically significant and P value was 
0.866 (Fig.8) 
3.4.5. Gpx1 
Mean serum Gpx1 of cases and controls was 247.24 µg/ml and 302.42 
µg/ml respectively. The mean was lower in the group of cases than in the 
group of controls, the difference was statistically significant and P value was 
0.001.(Fig.8). 
3.5. Effect of severity of asthma on serum Cu/Zn SOD, Gpx1, Se, Zn 
and Cu on stage 2 classified cases and comparison with controls 
3.5.1. Selenium 
Mean serum selenium of mild persistent cases and severe persistent cases 
was 0.474 mg/L and 0.557 mg/L respectively. The mean was lower in mild 
persistent cases than that of severe persistent cases. The difference was not 
statistically significant and P value was 0.869 (Fig.11, Table 1). 
Mean serum selenium of severe persistent cases and controls was 0.557 
mg/L and 1.03 mg/L. The mean was low in severe cases than controls. The 
difference was statistically significant and P value was 0.011 (Fig.11, Table 
2). 
Mean serum selenium of mild persistent cases and controls was 0.474 mg/L 
and 1.03 mg/L respectively. The mean was low in mild cases than in 
controls and the difference was statistically significant and P value was 
0.000 (Fig.11, Table 3). 
3.5.2. Zinc 
Mean serum zinc of mild persistent cases and severe persistent cases was 
0.666 mg/L and 0.533 mg/L respectively. The mean was lower in the group 
of severe cases than the group of mild cases, the difference was not 
statistically significant and P value was0.262 (Fig.11, Table 1) 
Mean serum zinc of severe persistent cases and controls was 0.533 mg/L and 
0.83 mg/L respectively. The mean was lower in the group of severe cases 
than the group of controls. The difference was statistically significant and P 
value was 0.002 (Fig.11, Table 2). 
Mean serum zinc of mild persistent cases and controls was 0.666 mg/L and 
0.83 mg/L respectively. The mean was significantly low in mild cases than 
controls and P value was 0.060 (Fig.11, Table 3). 
3.5.3. Copper 
Mean serum copper of mild persistent and severe persistent was 0.927 mg/L 
and 1.17 mg/L respectively. The mean was lower in the group of severe 
cases than the group of mild cases. The difference was not statistically 
significant and P value was 0.250 (Fig.11, Table1). 
Mean serum copper of severe persistent cases and controls was 1.17 mg/L 
and 1.51 mg/L respectively. The mean of severe cases was lower than that of 
controls. The difference was not statistically significant and P value was 
0.067 (Fig.11, Table 2). 
Mean serum copper of mild cases and controls was 0.927 mg/L and 1.51 
mg/L respectively. The mean of mild cases was lower than that of controls. 
The difference was statistically significant and P value was 0.000 (Fig.11, 
Table 3). 
3.5.4. Cu/Zn SOD 
Mean serum Cu/Zn SOD of mild persistent cases and severe persistent cases 
was 80.64 µg/ml and 98.21 µg/ml respectively. The mean was higher in the 
group of severe persistent cases than in the group of mild persistent cases. 
The difference was not statistically significant and P value was 0.134(Fig 
10, Table 1). 
Mean serum Cu/Zn SOD of severe persistent cases and controls was 98.21 
µg/ml and 87.6µg/ml respectively. The mean was higher in the group of 
severe persistent cases than the group of controls. The difference was not 
statistically significant and P value was 0.508 (Fig.10, Table 2). 
Mean serum Cu/Zn SOD of mild persistent cases and controls was 
80.64µg/ml and 87.6 µg/ml respectively. The mean in mild cases was lower 
than that of controls. The difference was not statistically significant and P 
value was 0.647 (Fig.10’ Table 3). 
3.5.5. Gpx1 
Mean serum Gpx1 of mild persistent cases and severe persistent cases was 
242.14µg/ml and 258.43µg/ml respectively. The mean was higher in group 
of severe cases than the group of mild cases. The difference was not 
statistically significant and P value was 0.646 (Fig.10, Table 1). 
Mean serum Gpx1 of severe persistent and controls was 258.43 µg/ml and 
302.42 µg/ml respectively. The mean was lower in the severe persistent 
cases than the group of controls. The difference was not statistically 
significant and P value was 0.54 (Fig.10, Table 2). 
Mean serum Gpx1 of mild persistent cases and controls was 242.14µg/ml 
and 302.4µg/ml respectively. The mean was lower in the mild cases than 
that in controls. The difference was statistically significant and P value was 
0.001 (Fig.10, Table 3). 
3.6. The levels of serum Cu/Zn SOD, Gpx1, Se, Zn and Cu in cases 
during acute attack and during stable periods and comparison with 
controls 
3.6.1. Selenium 
Mean serum selenium in cases during acute attack and during stable period 
was 0.534 mg/L 0.390 mg/L respectively. The mean was higher in the cases 
during acute attack than that of cases during stable period. The difference 
was not statistically significant and P value was 0.741 (Table 4). 
Mean serum selenium in cases during acute attack period and in controls 
was 0.534mg/L and 1.038 mg/L respectively. The mean was significantly 
lower in cases during acute attack period than in controls and P value 0.001 
(Table 5). 
Mean serum selenium in cases during stable period and in controls was 
0.390 mg/L and 1.038 mg/L respectively. The mean was statistically 
significant lower in cases during stable period than that of controls and P 
value was 0.003 (Table 6). 
3.6.2. Zinc 
The mean serum zinc in cases during the period of acute attack and in cases 
during stable period was 0.672 mg/L and 0.501 mg/L respectively. The 
mean in the cases during the attack was higher than that of stable cases. The 
difference was not statistically significant and P value was 0.196 (Table 4). 
The mean serum zinc in cases during acute attack and in controls was 0.672 
mg/L and 0.830 mg/L respectively. The mean was lower in cases during 
acute attack than in controls. The difference was not statistically significant 
and P value was 0.067 (Table 5). 
The mean serum zinc cases during stable period and  in controls was 0.501 
mg/L and 1.038 mg/L respectively. The mean was significantly lower in 
cases during stable period than in controls and P value was 0.004 (table.6) 
3.6.3. Copper 
Mean serum copper in cases during acute attack and during stable period 
was 1.00 mg/L and 1.01 mg/L respectively. There was no observed 
difference in the mean between the two groups and P value was 0.953 
(Table4). 
The mean serum copper in cases during acute attack and in controls was 
1.00 mg/L and 1.51 mg/L respectively. The mean was statistically 
significantly lower in cases during acute attack than in controls and P value 
was 0.000 (Table 5). 
The mean serum copper in cases during stable period and in controls was 
1.01 mg/L and 1.51mg/L respectively. The mean was statistically 
significantly lower in cases during stable period than that of controls and P 
value was 0.037 (Table 6). 
3.6.4. Cu/Zn SOD 
Mean serum Cu/Zn SOD in cases during acute attack and during stable 
period was 84.95 µg/ml and 102.78µg/ml respectively. The mean was lower 
during acute attack than that during stable period. The difference was not 
statistically significant and P value was 0.151 (Table 4). 
Mean serum Cu/Zn SOD in cases during acute attack and in controls was 
84.95 µg/ml and 87.68µg/ml respectively. The mean was low in cases 
during acute attack than that of controls. The difference was not statistically 
significant and P value was 0.934 (Table 5). 
Mean serum Cu/Zn SOD in cases during stable period and in controls was 
102.78 µg/ml and 87.67 respectively. The mean was higher in cases during 
stable period than that of controls. The difference was not statistically 
significant and P value was 0.277 (Table 6). 
3.6.5. Gpx1 
Mean serum Gpx1 in cases during acute attack and stable period was 
213.µg/ml and 307.73 µg/ml respectively. The mean was lower in the cases 
during acute attack than in the cases during stable period. The difference was 
statistically significant and P value was 0.000 (Table 4). 
Mean serum Gpx1 in cases during acute attack and in controls was 
213.0µg/ml and 302.42µg/ml respectively. The difference was significantly 
lower in cases during attack than in controls and P value was 0.000 (Table 
5). 
Mean serum Gpx1 in cases during stable period and in controls were 
302.42µg/ml and 307.73µg/ml respectively. The mean was higher in cases 
during stable period than that of controls. The difference was not statistically 
significant and P value was.950 (Table 6). 
3.7. Effect of gender on the level of zinc and copper in asthmatic 
patients 
3.7.1. Effect on zinc 
Mean serum zinc in female cases and in male cases was 0.68 mg/L and 
0.56mg/L respectively. The mean was higher in the group of female cases 
than the group of male cases. The difference was not statistically significant 
and P value was 0.122 (Table 7). 
3.7.2. Effect on copper 
Mean serum copper in female cases and in male cases was 1.07 mg/L and 
0.91 mg/L respectively. The mean was higher in the group of female cases 
than in the group of male cases. The difference was not statistically 
significant and P value was 0.285 (Table 7). 
3.8. Serum level of Cu/Zn SOD, Gpx1, Se, Zn and Cu for the same case 
during attack and after attack (paired samples)  
3.8.1. Zinc 
Mean serum zinc during the attack and after the attack was 0.8033 mg/L and 
0.5928 mg/L respectively. The mean during the attack was higher than that 
after the attack (Table 8). 
3.8.2. Copper 
Mean serum copper during the attack and after the attack was 1.01 mg/L and 
1.02 mg/L respectively. No difference in the mean during the attack and 
after the attack (Table 8). 
3.8.3. Selenium 
Mean serum selenium during the attack and after the attack was 0.65 mg/L 
and 0.42 mg/L respectively. The mean during the attack was higher than that 
after the attack (Table 8). 
3.8.4. Cu/Zn SOD  
Mean serum of Cu/Zn SOD during the attack and after the attack was 
99.0µg/ml and 38 µg/ml respectively. The mean during the attack was 
higher than that after the attack (Table 8). 
3.8.5. Gpx1 
Mean serum Gpx1 during the attack and after the attack was 158.5 µg/ml 
and 191.5 µg/ml respectively. The mean was lower during the attack than 
that after the attack (Table 8). 
  
  
 
 
Table 1: Level of serum Cu/Zn SOD and Gpx1 in µg/ml and Se, Zn and Cu  
In mg/L of mild and severe cases (mean ± SEM) 
 (n) Mean ± SEM P value 
SOD mild (µg/ml) 
SOD severe (µg/ml) 
56 
28 
80.64 ± 4.871 
98.21 ± 7.761 
0.134 
Gpx1 mild (µg/ml) 
Gpx1 severe (µg/ml) 
57 
35 
242.14 ± 10.764 
258.43 ± 15.838
0.646 
Se mild (mg/L) 
Se severe (mg/L) 
33 
19 
0.474 ± 0.0463 
0.557 ± 0.114 
0.869 
Zn mild (mg/L) 
Zn severe (mg/L) 
35 
19 
0.666 ± 0.050 
0.533 ± 0.059 
0.262 
Cu mild (mg/L) 
Cu severe (mg/L) 
35 
19 
0.927 ± 0.080 
1.17 ± 0.137 
0.250 
 
  
  
 
 
 
Table 2: Serum level of Cu/Zn SOD and Gpx1in µg/ml and Se, Zn, and Cu 
 In mg/L of severe cases and controls (mean ± SEM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 (n) Mean ± SEM P value 
SOD Severe (µg/ml) 
SOD Controls (µg/ml) 
28 
45 
98.21 ± 7.761 
87.67 ± 5.46 
0.508 
Gpx1 Severe (µg/mL) 
Gpx1 Controls (µg/mL)
35 
48 
258.43 ± 15.83 
302.42 ± 10.145 
0.54 
Se Severe (mg/L) 
Se Controls (mg/L) 
19 
36 
0.557 ± 0.114 
1.038 ± 0.219 
0.011 
Zn Severe (mg/L) 
Zn Controls (mg/L) 
19 
34 
0.533 ± 0.0599 
0.830 ± 0.047 
0.002 
Cu Severe (mg/L) 
Cu Controls 
19 
33 
1.17 ± 0.137 
1.51 ± 0.0845 
0.067 
  
 
 
Table 3: Serum level of Cu/Zn SOD, Gpx1 in µg/ml and Se, Zn, and Cu in 
mg/L of mild cases and controls (mean ± SEM) 
 
 (n) Mean ± SEM P value 
SOD mild (µg/mL) 
SOD Controls (µg/mL) 
56 
45 
80.64 ±4.871 
87.67 ± 5.464 
0.647 
Gpx1 mild (µg/mL) 
Gpx1 Controls (µg/mL)
57 
48 
242.14 ± 10.764
302.42 ± 10.145
0.001 
Se mild (mg/L) 
Se controls (mg/L) 
33 
36 
0.474 ± 0.0463 
1.038 ±0.219 
0.000 
Zn mild (mg/L) 
Zn controls (mg/L) 
35 
34 
0.666 ± 0.050 
0.830 ±0.044 
0.060 
Cu mild (mg/L) 
Cu controls (mg/L) 
35 
33 
0.927 ± 0.080 
1.51 ± 0.084 
0.000 
 
 
  
  
 
 
 
       Table 4: Serum level of Cu/Zn SOD and Gpx1 in µg/ml and Se, Zn, and Cu in  
      mg/ml of symptomatic during attack and asymptomatic stable cases(mean ± 
SEM) 
 (n) Mean ± SEM P value 
SOD during attack (µg/ml) 
SOD stable(µg/ml) 
55 
23 
84.95 ± 9.096 
102.78 ± 7.363 
0.151 
Gpx1 during attack (µg/ml) 
Gpx1 stable(µg/ml) 
54 
33 
213.00 ± 9.739 
307.73 ± 13.848 
0.000 
Se during attack (mg/L) 
Se stable (mg/L) 
36 
12 
0.534 ± 0.0673 
0.390 ± 0.0676 
0.741 
Zn during attack (mg/L) 
Zn stable (mg/L) 
38 
12 
0.672 ± 0.0489 
0.5015 ± 0.0676 
0.196 
Cu during attack (mg/L) 
Cu stable (mg/L) 
37 
12 
1.0 ± 0.0878 
1.01 ± 0.1635 
0.953 
 
 
  
  
 
 
 
Table 5: Serum level of SOD and Gpx1 in µg/ml and Se, Zn, and Cu  
In mg/L of cases during attack and controls (mean ± SEM) 
 (n) Mean ±.SEM P value 
SOD during attack (µg/ml) 
SOD controls (µg/ml)  
55 
45 
84.95 ±.4.59 
87.67 ±.5.464 
0.934 
Gpx1 during attack (µg/ml)
Gpx1 controls (µg/ml) 
54 
48 
213.0  ±.9.739 
302.42 ±.10.145
0.000 
Se during attack (mg/L) 
Se controls (mg/L) 
36 
36 
0.534 ±.0.0673 
1.038 ±.0.1219 
0.001 
Zn during attack (mg/L) 
Zn controls (mg/L) 
38 
34 
0.672 ±.0.0448 
0.830 ±.0.0473 
0.067 
Cu during attack (mg/L) 
Cu controls(mg/L) 
33 
33 
1.0 ±.0.0878 
1.51 ±.0.0843 
0.000 
 
  
  
 
 
 
 
Table 6: Serum level of SOD and Gpx1 in µg/ml and Se, Zn, and Cu  
In mg/L of stable cases and controls (mean ± SEM) 
  (n) Mean ± SEM P value 
SOD stable (µg/mL) 
SOD controls (µg/mL) 
23 
45 
102.78 ± 8.938 
87.67 ± 5.464 
0.277 
Gpx1 stable (µg/mL) 
Gpx1 control (µg/mL) 
33 
48 
307.73 ± 13.84 
302.42 ± 10.145
0.950 
Se Stable (mg/L) 
Se controls (mg/L) 
12 
36 
0.390 ± 0.067 
1.038 ± 0.1219 
0.003 
Zn stable (mg/L) 
Zn controls (mg/L) 
12 
34 
0.501 ± 0.0676 
0.830 ± 0.0473 
0.004 
Cu stable (mg/L) 
Cu controls (mg/L) 
12 
33 
1.01 ± 0.1635 
1.51 ± 1.344 
0.037 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
Table 7: Serum level of Zn and Cu in mg/L in female and  
males of classified cases (mean ± SEM) 
Serum (mg/L) Females Males P value
Zn 0.68 0.56 0.122 
Cu 1.07 0.91 0.285 
 
 
  
  
 
 
 
Table 8: Serum concentration of Zn, Cu, Se in mg/ml Cu/Zn SOD  
and Gpx1 in mg/L of Paired samples (during and after attack) 
Mean serum of During attack After attack 
Zinc (mg/L) 0.8033 0.5928 
Copper (mg/L) 1.00 1.01 
Selenium (mg/L) 0.65 0.42 
Cu/Zn SOD (µg/ml) 99.0 38.0 
Gpx1 (µg/ml) 158.5 191.5 
  
 
 
 
 
4. Discussion 
Bronchial asthma is defined as a bronchial chronic inflammatory disease in 
which patients tend to have increased oxidative stress caused by imbalance 
between oxidants and antioxidants. There are various antioxidant enzymes 
eliminating excess overproduced oxidants. Trace elements such as zinc, 
copper and selenium are essential components of the antioxidant enzymes, 
Cu/Zn SOD and Gpx.(135)  
The result of this study adds to the growing body of evidence, demonstrating 
that the pathophysiology of asthma is associated with alterations in the level 
of oxidants and antioxidants. 
The study was hospital based case control, carried in two stages. In the first 
stage, serum trace elements of zinc, copper, selenium and magnesium were 
measured in adult asthmatic patients, most of them frequently attending to 
asthma clinics and rooms of emergency departments with acute asthma 
attacks, and treated with asthma therapies. In this stage of the study a 
correlation between trace elements and bronchial asthma was reported. It was 
revealed that the serum concentration of zinc in bronchial asthma patients was 
significantly higher than that of controls; serum selenium and copper were 
significantly lower than controls. Regarding serum magnesium, no difference 
was obtained between patients and controls. 
The findings of the first stage draw the attention to explore the role of 
antioxidants in asthmatic patients in a second study. In this stage, patients 
were grouped, as mild and severe cases of asthma according to asthma 
severity (16) and to symptomatic during the period of attack and asymptomatic 
during the stable period and while administered with asthma protocols of 
drugs.(17) Serum level of zinc, copper and Cu/Zn SOD enzyme, serum Se and 
Se dependant antioxidant enzyme Gpx1 were measured. 
 
 
The second stage of the study demonstrated increased serum zinc of 
symptomatic patients who presented with acute attack during the first hour of 
treatment with asthma therappies. This demonstration is proportional to the 
findings of the stage 1 where the level of zinc was found high. Although the 
cases of stage 1 were not classified but the majority of them were 
symptomatic patients recruited from emergency asthma rooms. The increased 
level might be due to the inhaled corticosteroid administered to those patients.  
These findings were similar to the findings of Lurina et al who reported  a 
high concentration of  zinc in whole blood of asthmatic patients who had 
received  glucocorticosteroids as basic therapy.(136) Nevin Uzuner et al,(137) 
reported that zinc level was detected lower in stable a symptomatic cases and 
increased with treatment of inhaled corticosteroid through increase of anti 
inflammatory and antioxidants effects.   
Serum zinc in the cases classified by severity of asthma was found to be 
decreased in both mild and severe groups compared to healthy non asthmatic 
controls. The first  study  that investigated zinc status of bronchial asthma was 
that of Goldy et al. in 1984 who reported a reduction in zinc content of hair in 
asthmatics.(74)Many other studies have reported that serum zinc concentration 
in bronchial asthma patients tended to be lower, (25, 73, 75, 76, 138-141) these 
findings were similar to the findings of this study as the level significantly 
decreased in cases compared to controls. Studies on zinc level revealed 
controversial findings. A cohort study in Japanese reported significantly 
increased zinc level in females asthmatics compared to controls, but no 
difference in zinc level between asthmatic males and controls.(135)  
On the other hand other study reported increased zinc level in asthmatic 
patients.(142) A study on Nigerian asthmatics reported no significant difference 
in the level of zinc between patients and controls. (82) Similar findings were 
reported by Tricia (2004) and Picado (2001).(143, 144)  
 
 
Copper and zinc levels in body usually has an antagonistic relationship where 
the decrease in serum zinc is accompanied by increase of serum copper and 
decreased copper level causes increased serum zinc. 
In stage 1 asthma cases copper was found significantly decreased in patients 
compared to controls, while zinc was increased. This finding  is similar to 
Akingugbe (1987) (142) who found decreased copper and increased zinc in 
asthmatic children. However, Anetor (2003) (82)  found no difference in both 
copper and zinc in asthmatic Nigerian compared to controls, but similar to the 
findings of this study, he  reported increased copper level in female 
asthmatics compared to males. 
 Interestingly increased zinc level in asthmatic females compared to asthmatic 
males was revealed by this study, though the increase was not statistically 
significant, and was related to gender differences in etiology.It has been 
previously proposed that the gender related differences in serum zinc and 
copper concentration may be explained by the dietary intake and efficacy of 
absorption, also it has been reported that treatment with exogenous estrogens 
or post menopausal therapy was associated with increased serum copper.(145) 
A number of investigators who found decreased zinc levels in asthmatics, 
they also reported increased copper in those patients.(73, 76, 140) 
In this study when all the patients were pooled together, significantly 
decreased copper level compared to controls was demonstrated, although no 
difference was found in symptomatic cases during attack and asymptomatic 
stable cases. This was similar to the findings  reported by Nevin Uzuner who 
found no difference in serum copper levels in the classified groups.(137) 
Another findings were reported by Whig (1995) (141) who found no significant 
difference between patients and controls in serum copper level, but they 
noticed a decrease in zinc level in their patients. 
 
 
A novel study which characterized the elemental composition of exhaled 
breath condensate (EBC) in order to identify new biomarkers of exposure and 
susceptibility in asthmatic patients was observed by Antonio Mutti who 
reported reduced EBC copper in asthmatics.(146)  
Zinc and copper have strong mutual antagonism; high zinc intake induces 
intestinal cell metallothionin which binds copper and prevents its transfer into 
the blood. Eventually the intestinal cell die and slouph taking the trapped 
copper with them into the stools thus preventing copper absorption. (147) 
 Zinc helps to remove copper from its binding site because they have similar 
coordination chemistry; zinc is able to compete for copper binding site and 
push copper off the molecule.(147)This confirms the related roles of zinc and 
copper as they are functioning together in the antioxidant Cu/Zn SOD. A 
higher zinc intake decreases the absorption of copper and high blood copper 
content can depress zinc absorption from intestine, so the balance between the 
two nutrients is important. 
The Cu/Zn SOD serum concentration was found decreased in this study in 
patients compared to controls, and it also decreased during the attack 
compared to stable cases. Mice over expressing Cu/Zn SOD are resistant to 
allergen induced lung toxicity.(148) suggesting that SOD is important in the 
pathogenesis of allergic inflammation and asthma. These suggestions were in 
agreement, with most human studies. SOD activity decreases in the bronchial 
epithelium (~50%), in the cells of broncho alveolar lavage (25%), and in 
bronchial brushings (nearly 50%) in patients with asthma compared with 
control subjects.(78, 131) Acute antigen instillation into  the lungs of individuals 
with atopic asthma also lead to rapid 50% decrease in SOD activity in the 
bronchoalveolar lavage cells of these individuals.(131)  
Similar to the findings of this study, Katsoulis, et al, demonstrated decreased 
SOD activity in cases with exacerbation of asthma. This activity was 
 
 
significantly improved once the respiratory parameters of asthmatic patients 
returned to normal values,(149) this was confirmed by this study findings as  
SOD level increased in stable cases where there was less oxidant stress, and in 
severe cases being more exposed to regular steroid treatment. However, and 
in line with the findings of this study several reports have found alterations of 
different antioxidants in asthma. Recent literature in this field seems to 
indicate conflicting findings. For instance, lower serum SOD activity has been 
reported in mild adult asthmatics compared with controls.(125, 150) This is 
consistent with the lower level of SOD which have been found in mild cases 
in this study and also agreed with the study which reported a low level of 
SOD in mild asthmatic children.(151) However, in contrast to this report, 
increased SOD activity in red blood cells was demonstrated (152) and  also a 
higher level in mild stable asthmatics have been observed.(153) 
Antioxidant enzymes, such as SODs play an important role in offering 
protection to the airways against oxidative stress. SODs get inactivated by 
reactive oxygen and nitrogen species. Thus antioxidant defense is impaired in 
hyperactive airways. The situation gets further aggravated during acute 
exacerbation of asthma. The inflammatory cells increase the production of 
ROS. There is localized decrease in SOD activity within inflamed asthmatic 
airways.(58) 
Comhair  and colleagues grouped 115 asthmatics to 40 with severe asthma 
and 75 with non severe. They hypothesized that asthmatic individuals having 
greater amount of oxidative stress may have markedly decreased SOD 
activity. (125) This  confirms the findings of this study that there was decreased 
SOD during attack where there was more oxidative stress. This should reflect 
loss of circulating SOD activity and development of severe asthma and/or 
worsening of airflow limitation. 
 
 
It is clear that profound variations in copper and zinc status occur during the 
course of acute and chronic inflammation such as bronchial asthma.(140)As 
both Zn & Cu form the prosthetic group of SOD, any alteration in their level 
affects activity of the enzyme. It is debatable whether an increase in copper 
level has an impact upon SOD expression. However, a decrease in this 
element impairs the enzyme activity. Such a condition may cause oxidative 
stress or may further increase the existing stress. When the contents of copper 
or zinc decrease, Cu-Zn-SOD activity also diminishes, and free radicals lead 
to increased lung injury.(25) 
The activity levels of serum extra cellular Cu/Zn SOD are known to be 
decreased with inflammation in rats. It is not known whether the depression 
results from decreased copper availability to the enzyme pool, reduced 
synthesis of the enzyme or enzyme inactivation unrelated to copper cofactor. 
Human erythrocyte SOD activity was reduced by intentionally feeding a high 
fructose, marginal copper to men from a wide age range, SOD activity then 
increased again after a period of supplementation.(154) 
Human erythrocyte SOD activity was also depressed by oral supplementation 
with zinc, an element that can antagonize copper absorption, besides their 
competition for the same absorptive side or a similar protein system.(155) 
Regarding the role of zinc on Cu/Zn SOD, conflicting findings were reported 
by many investigators. Soutar et al. reported that the group with limited 
intake of zinc had higher risk of asthmatic attack.(156) Thus it had been 
considered that reduction in an antioxidant functions and increased risk of 
bronchial asthma were due to decline of SOD activity led by insufficient zinc 
concentration in serum.(156) 
A number of researchers on animals reported that a positive correlation 
between serum zinc concentration and SOD activity was seen.(157, 158) 
However many studies on human showed a decreased SOD activity when 
 
 
serum zinc concentration was increased.(159, 160) Yadrick et al. and Ficher et al 
suggested that SOD activity declined due to an elevation of serum zinc 
concentration, and led to decline in copper concentration.(155) 
As copper deficiency reflects a high turnover of cu/Zn SOD, therefore an 
increase in serum Zn concentration indirectly decreases SOD activity by 
making copper less available. However, a study by Davis et al. reported that 
serum zinc concentration was elevated and SOD activity was raised 
simultaneously when subjects were administered with zinc and copper 
supplementations.(161) This study reported a decrease in SOD serum 
concentration, increase of serum zinc concentration and with no change in 
serum copper concentration during the attack of asthma and following 
inhalation of gluco-cortico steroids. It was documented that such conditions 
induces an imbalance between oxidants and antioxidants, and consequently 
gives excessive oxidative stress. The results of this study supported this 
hypothesis. 
The mechanism of an association between bronchial asthma and serum zinc in 
less severe patients could vary from that in severe patients, and it may have 
induced the discrepancy of results between stage 1 and stage 2 patients. 
Similarly this study reported decreased level of Cu/Zn SOD in cases with 
acute exacerbation compared to controls. Interestingly our findings revealed 
improved level of SOD in severe cases compared to mild cases and controls. 
These discrepancies may be due to corticosteroids, as the effects of steroids 
on antioxidant status have been investigated revealing possible positive 
effects on the reduced antioxidant enzyme activity. It is possible that 
antioxidant enzyme activity is regulated at the level of transcription, 
additionally because of the fact that antioxidant enzymes are trace elements 
dependant; steroids may affect their activities through influence on trace 
elements accumulation.(118) 
 
 
Adminstration of cortico steroids is associated with a decrease in oxidative 
stress. Parenteral cortico steroids improve SOD activity in patients with 
asthma.  (125) which confirms the findings of this study in severe cases, where 
the level was more improved in severe cases as they were given parenteral 
corticosteroids. 
This study reported no difference in serum concentration of Mg in asthmatics 
and controls. Epidemiological evidence suggests that a low dietary intake of 
magnesium increase sensitivity, and wheezing. It was found that a high 
magnesium intake is associated with improvement in symptom scores in 
stable asthmatic subjects, though not in objective measures of air flow or 
airway reactivity, in stable asthmatic subjects. Magnesium has several 
biological effects of potential relevance to asthma, including broncho -
dilatation when given intravenously in acute severe asthma.(162)Other findings 
which were similar to the findings of this study reported that there was no 
change in magnesium level between cases and controls.(25, 143, 163-165) On the 
other hand, these results were at variance with the results reported by some 
investigators, Anetor et al, found lower magnesium level in severe asthmatics 
group than in controls.(82) Also Hashimuto et al.(166)    reported that 
hypomagnesaemia was common in asthmatics, and magnesium level 
decreased in very severe cases. 
Selenium is a key component of a number of functional selenoproteins like 
glutathione peroxidase (Gpx), which reduces hydrogen peroxidase and other 
organic peroxides to nontoxic substances. Serum selenium level is very 
important for the activity of the glutathione peroxidase in the pulmonary 
antioxidant systems.(79) 
Studies performed to determine a possible relationship between selenium 
levels and asthma has yielded a contradictory results. Serum selenium level in 
this study was found significantly low in all asthmatic patients compared to 
 
 
controls. This report was in agreement with Kadrabova et al,(1996)(73), who 
found decreased selenium status in asthma, and Flatt (1990)who reported 
reduced selenium in asthmatic subjects in New Zealand. (79, 80, 115) Also 
Hasselmark (1993) reported lower selenium in Australian asthmatics, and 
early case control studies in New Zealand demonstrated decreased selenium 
levels in patients with asthma (1999-2000-2001), and this finding has been 
confirmed more in the United Kingdom (2001). Qujeq Hidari reported that 
mean serum selenium was lower in intrinsic asthmatic subjects than in none 
asthmatic. The results of this study confirm these findings.(167) 
Also this study reported improvement in the level of serum selenium during 
the symptomatic period in severe cases treated with corticosteroids, compared 
to the level of the stable asymptomatic cases. As it was postulated that 
corticosteroids may decrease the excretion rate of the element and may thus 
exert a positive effect antioxidant in individuals with established low 
selenium status.(168)Rachel N. Rubin, Livia Navon and Patricia A. Cassano, 
(2004), studied the relationship of serum selenium to asthma prevalence in 
youth, and found a strong significant inverse association, that suggests a 
potential role for selenium in disease. On the other hand, other studies 
reported no difference in serum levels of selenium in asthmatics compared to 
control subjects.(85) 
Human dietary intake of Se ranges from high to low according to geography. 
A dietary intake of selenium is falling in some parts of the world notable for 
their low soil content. These falling intakes are reflected in diminishing serum 
and whole blood selenium concentrations. Serum Se values of 1.0 mg/L are 
believed to be required for optimal activity of glutathione peroxidase, and the 
activity of Gpx may indicate the status in selenium. In this study the selenium 
dependant Gpx1 was found significantly low in asthmatic patients when 
compared to controls. Individuals with asthma tend to have increased 
 
 
oxidative stress,  and decreased activity of Gpx,(73, 79) Similarly Quigi et al, 
found lower activity of Gpx measured in serum of asthmatics compared to 
non- asthmatics.(167) Furthermore, nitric oxide (No) which increased in asthma 
especially during exacerbation is capable of inactivating Gpx.(169) 
In this study serum Gpx1 was found significantly decreased in cases during 
the symptomatic attack. The level also decreased in severe cases and mild 
cases compared to controls. The difference was significant in the mild cases.  
.In a study which analyzed the degree of defense against ROS in Maltese 
asthmatics, no significant difference was found in Se and erythrocyte Gpx 
activity between patients and controls. Interestingly this study recorded 
improvement in the level of Gpx in stable severe cases compared to the level 
in cases during the attack. Opposite to the findings of this study, investigators 
(78, 121) found Gpx levels in asthmatic lung cells similar to controls. Comhair 
also found no difference in total Gpx activity between asthmatics and 
controls.(131) Jacobson et al demonstrated an elevated plasma selenium levels 
or Gpx  activity  with acute severe asthma (170) a result which was in line with 
this study, and consistent with an adaptive upregulation to protect against 
oxidative stress. 
Interestingly in this study when Gpx1 was measured during the attack and 
after the attack for the same patients in four cases, the result demonstrated 
elevated Gpx level after the attack, and decreased level during the attack, 
whereas  SOD level decreased significantly in the same cases after the attack. 
This was consistent with increased ROS formation by inflammatory and 
epithelial cells in the lungs leading to alteration in intracellular and 
extracellular reducing/oxidizing environment GSH/GSSG levels. Loss of 
SOD antioxidant activity was present in asthma and favors increased ROS 
formation, the high level of ROS leads  subsequently to induction of e Gpx 
mRNA transcription protein trascriptor, protein expression and secretion into 
 
 
ELF since susceptibility of cells to ROS depends largely on the ability to up 
regulate protective antioxidant system.(170) Improved selenium level was 
noticed after the attack in the four cases, which may be an effect of 
corticosteroids. Consequently Gpx1 also improved, a finding which was also 
consistent with a study by Jeong who noticed that selenite administration to 
allergin sensitized mice increased the selenium dependant Gpx in lung 
tissue.(171) As for Zn in these four cases it decreased after the attack coinciding 
with SOD decrease, which supports the assumption of the role of zinc in SOD 
level. 
The results of the four cases showed that there is an important role of steroids 
in treatment of asthma through increase of antioxidant capacity to overcome 
the effect of oxidant stress in asthma. This draw the attention for the need of a 
longitudinal study with large sample size and hospital follow up. 
  
 
 
 
Conclusions 
• Oxidant stress has a role in asthma etiology in Sudanese patients and the 
ability of defense from oxidant stress by antioxidant is impaired in asthma 
patients. 
• Increased zinc level in symptomatic patients during attack compared to a 
symptomatic stable patients. 
• Significantly decreased zinc level in severe cases compared to controls 
• Copper and Zinc are inversely related, in their serum concentrations. 
• The levels of copper do not change during the period of the attack and 
during the stable period, although it is decreased in both mild and severe 
cases compared to controls. 
• Zinc and Copper levels are insignificantly high in asthmatic females 
compared to asthmatic males; there are gender variations due to other 
physiological contributions. 
• Cu/Zn SOD decreased in asthmatic patients compared to controls. A low 
level in symptomatic cases compared to asymptomatic was recorded. The 
level improved in severe cases compared to mild cases and controls.  
• Selenium is significantly decreased in asthmatics compared to controls. 
The level of Selenium increased in symptomatic cases during the attack 
compared to stable cases. Therapeutic interventions improve selenium 
level. 
• Gpx1 is significantly decreased in asthmatic patients compared to controls, 
and steeply decreased according to severity and symptomatology 
• Magnesium level does not show any significant difference between 
patients and controls. 
  
 
 
Recommendations: 
• Further longitudinal studies involving larger number of patients from 
different hospitals & different areas of Sudan are needed to consolidate the 
findings of this study. 
• Efforts should be put on identifying the reference range of serum trace 
elements in our home population in Sudan. 
• Further studies on the relationship between asthma and trace elements and 
the mechanism of action are needed. 
• Interpretation should consider clinical phases and therapies, and further 
studies should consider types of cortico steroids given, dose, and duration 
of the drug.  
• Studies on soil contents of these trace elements should be done to improve 
these ingredients in nutrients, and directing intake by general advise on 
diet for patients with asthma needs to be based on evidence. 
• Supplementation of asthmatic patients with these micronutrients may play 
a role in improving their conditions.  
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Appendix-I 
 
GINA Classification of Asthma Severity 
  Symptoms/Day Symptoms/Night PEF or FEV1 PEF 
variability
STEP 1 
Intermittent 
< 1 time a week 
 
Asymptomatic and 
normal PEF 
between attacks 
</= 2 times a 
month 
  
>/= 80% 
  
< 20% 
  
STEP 2 
Mild 
Persistent 
> 1 time a week 
but < 1 time a day 
 
Attacks may affect 
activity 
> 2 times a 
month 
  
>/= 80% 
  
20-30% 
  
STEP 3 
Moderate 
Persistent 
Daily 
 
Attacks affect 
activity 
> 1 time a week 
  
60%-80% 
  
> 30% 
  
STEP 4 
Severe 
Persistent 
Continuous 
 
Limited physical 
activity 
Frequent 
  
</= 60% 
  
> 30% 
  
  
PEF, Peak Expiratory Flow; FEV1, Forced Expiratory Volume in the first second. 
• The presence of one of the features of severity is sufficient to place a patient in that 
category. 
• Patients at any level of severity-even intermittent asthma-can have severe attacks. 
  
  
 
 
Appendix-II 
Questionnaire 1 
 
Serial No‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
 
Name‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐Age‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐Sex‐‐‐‐‐‐ 
 
Occupation‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
 
 
Residence‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
 
Address‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
 
Date of Onset OF Asthma? 
 
Since birth‐‐‐‐‐‐‐‐‐‐‐‐‐< 10 years‐‐‐‐‐‐‐‐‐‐‐‐‐‐>10 years‐‐‐‐‐‐‐‐‐‐‐‐>20 years‐‐‐‐‐ 
   
Frequency of attendance to asthma clinics 
 
1‐Frequently‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐2‐ Not frequently‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
 
Drugs taken for control? 
 
Bronchodilator  inhaler‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐steroid  inhaler‐‐‐‐‐‐‐‐‐‐‐‐‐steroid tablets‐‐‐‐‐‐‐‐‐‐
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐others‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
 
  
 
 
Appendix-III 
Questionnaire  2 
 
Serial No‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
Name‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐Age‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐Sex‐‐‐‐‐‐ 
Occupation‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
 
Residence‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
 
Address‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
 
Date of Onset OF Asthma? 
 
Since birth‐‐‐‐‐‐‐‐‐‐‐‐‐< 10 years‐‐‐‐‐‐‐‐‐‐‐‐‐‐>10 years‐‐‐‐‐‐‐‐‐‐‐‐>20 years‐‐‐‐‐ 
   
Clinical  Classification of severity 
 
1‐Mild Persistent‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐2‐ Severe persistent‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐
‐‐ 
Drugs taken for control? 
 
Bronchodilator  inhaler‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐steroid  inhaler‐‐‐‐‐‐‐‐‐‐‐‐‐steroid tablets‐‐‐‐‐‐‐‐‐‐
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐others‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
   
 
 
 
Appendix-IV 
Spectrophotometer  procedure for selenium measurement 
 
 
Trace element determination of Se had been carried out using Varian SpectrAA 220 Atomic 
Absorption Spectrometer equipped with a graphite furnace atomizer and an auto-sampler. The spectral line 
used for Se determination was 196.0 nm. The calibration graph was constructed applying standard addition 
technique. Sample volume injected into the graphite furnace atomizer was 20 µL plus a suitable volume of 
the stock standard solution of Se (100 µg/L) added to form 0, 10, 20, 30 and 40 µg/L of Se. The diluting 
agent used for determination consisted of 0.5 % Triton X-100, 0.125 % Dw Coming Antifoam-B and 0.25 % 
Ascorbic Acid. Ten micro-liters of Palladium solution (1000 mg/L) were used as a matrix modifier. Matrix 
modifier was pre-injected and dried then the sample volume was injected. The total volume of sample, 
diluting agent and matrix modifier was 40 µL. The temperature program includes maximum drying 
temperature of 300 C, ashing temperature of 1200 C and atomization temperature of 2700 C.  
 
 
Spectrophotometer Procedure for Zn, Cu, and Mg     
 
 
Trace element determination of Zn, Cu, and Mg had been carried out using Varian SpectrAA 220 
Flame Atomic Absorption Spectrometer. The spectral lines used for determination were 213.9 nm for Zn, 
324.7 nm for Cu and 285.2 nm for Mg. The calibration graphs were constructed applying normal aqueous 
standards.   
Serum samples were diluted 1:5 with double distilled water.  Only for some samples, the dilution 
factor is 1:7. Each measured element concentration includes three replicates of the measured element.  
 
Flame Atomic Absorption Spectrometry- Analytical Methods, Varian, Publication No. 85- 100009-00, 
Australia, 1989.  
  
 
 
Appendix_V 
 
 
ELIZA Procedure of Cu/Zn SOD 
‐ Pre dilute samples with PBS 1:20 before  starting with the test procedure. 
‐ Wash the micro well strips twice with approximately 400µl Wash Buffer per well 
with thorough aspiration of micro well contents between washes. 
‐ Add 100µl of PBS in duplicate to the blank wells. 
‐ Add 90µl of PBS to the sample wells. 
‐ Add 10µl of each pre diluted sample in duplicate to the sample wells. 
‐ Add 50µl of HRP-Conjugate to all wells. 
‐ Cover with an adhesive film and incubate at room temperature for 1 hour on a 
micro plate shaker  set   at 100 rpm. 
‐ Remove adhesive film and empty  wells . Wash micro well strips 3 times. 
‐ Pipette 100µl of TMB Substrate Solution to all wells. 
‐ Stop the enzyme reaction by quickly pipetting  100 µl of stop solution in to each 
well. 
‐ Read  absorbance of each micro well on a spectrophotometer using 450nm as wave 
length. Determine the absorbance of both samples and the standards.  
 
  
 
 
Appendix_VI 
 
ELIZA Procedure for Gpx1 Assay: 
‐ Add 300µl of incubation buffer to all wells and incubate the plate for 5 minutes at 
room temperature. 
‐ Thoroughly   aspirate or decant the solution from the wells. Wash Wells 2 times  
‐ For the standard curve, add 100µl of the standard to the appropriate micro titer 
wells. Add 100µl of the standard/ sample dilution buffer to zero wells. 
‐ Serum requires at least20 fold dilution in the standard/sample dilution . Add 100µl 
of samples to each well. 
‐ Cover the plate with the plate cover and incubate for 2 hours at room temperature. 
‐ Thoroughly aspirate or decant the solutions from the wells. Wash the wells 3 times. 
‐ Pipette 100µl of working secondary antibody solution into each well. 
‐ Cover the plate  with the plate cover  and incubate for 1 hour at room temperature. 
‐ Thoroughly  aspirate or decant the solutions from the wells. Wash the wells 3 
times. 
‐ Add 100µl of” Working AV-HRP Solution” to each well. 
‐ Cover the plate with the plate cover and incubate for 30 minutes at room 
temperature. 
‐ Thoroughly aspirate or decant the solution from the wells. Wash the wells 3 times. 
‐ Add 100µl of substrate to each well. The liquid in the wells should begin to turn 
blue. 
‐ Incubate the plate at room temperature. 
‐ Add 100µl of Stop Solution to each well. The solution in the wells should change 
from blue to yellow. 
‐ Read the absorbance of each well at 450nm. Read the plate within 20 minutes of 
adding the Stop Solution. 
‐ Plot on graph paper the absorbance of the standard against the standard 
concentration. Draw a smooth curve through these points to construct the standard 
curve. 
‐ Read the human Gpx1 concentrations for the unknown samples and controls from 
the standard curve plotted. Multiply values obtained from the unknown sample by 
the dilution factor.  
 
 
